

SUPPORTING INFORMATION

Fragment-sized and bidentate (immuno)proteasome inhibitors derived from cysteine and threonine targeting warheads


Contents of Supporting Information:

1. Details of chemical syntheses	1
1.1. Preparation of benzoxazole-2-carbonitriles	1
1.2. Preparation of vinylthiazole-linked boronic acid derivative	4
1.3. Preparation of benzimidazole-2-carbonitrile-linked boronic acids	5
1.4. Preparation of chloro-substituted benzimidazole-2-carbonitrile-linked boronic acids	6
1.5. Preparation of benzoxazole-2-carbonitrile-linked boronic acids	7
2. Synthesized compounds	8
2.1. Synthesis of intermediates for the benzoxazole-2-carbonitrile library	8
2.2. Synthesis of benzoxazole-2-carbonitriles	10
2.3. Synthesis of boronic acid derivatives	17
3. LC-MS chromatograms, ¹ H NMR and ¹³ C NMR spectra of the synthesized compounds	34
4. Supplementary Tables and Figures	121
References	134

1. Details of chemical syntheses


1.1. Preparation of benzoxazole-2-carbonitriles

Appropriately substituted 2-aminophenol derivatives were used as synthetic starting materials. Most of them were commercially available, while 2-aminobenzene-1,4-diol (**II**) and 3-aminobenzene-1,2-diol (**VI**) were prepared in-house (Scheme S1). 2-Nitrobenzene-1,4-diol (**I**) was hydrogenated using Selcat-Q6 (10% Pd/C) as catalyst at room temperature and 8 bar hydrogen pressure to achieve complete conversion in 2 hours. 2-Aminobenzene-1,4-diol (**II**) was isolated after filtration and evaporation of the volatiles. 3-Aminobenzene-1,2-diol (**VI**) was prepared in two steps. Catechol (**III**) was first nitrated with fuming HNO₃ at 0 °C according to Cozza et al. [1]. The desired compound **IV** was formed as the minor product since the formation of 4-nitrobenzene-1,2-diol (**V**) prevailed. Interestingly, the formation of a small amount of dinitro-catechol (**VI**) could also be observed. After crystallization workup, 3-nitrobenzene-1,2-diol (**IV**) was obtained, which was hydrogenated as for the preparation of **II**. Complete conversion was achieved in 4 hours, whereby atmospheric hydrogen pressure was sufficient to give the desired 3-aminobenzene-1,2-diol (**VII**).



Scheme S1. Preparation of 2-aminobenzene-1,4-diol (II) and 3-aminobenzene-1,2-diol (VII).^a Reagents and conditions: (a) H₂/Pd/C, EtOH, RT, 8 bar, 2 h, 99%; (b) 90% HNO₃, Et₂O, 0 °C, 2 h to RT, 16 h, 10%; (c) H₂/Pd/C, MeOH, RT, 1 bar, 4 h, 98%

For the synthesis of benzoxazole-2-carbonitriles, the general synthetic method was very similar to that reported previously [2], *i.e.*, ring closure and incorporation of the nitrile warhead was achieved by 4,5-dichloro-1,2,3-dithiazolium chloride (Appel's salt) (Scheme S2).




Scheme S2. General methods for the synthesis of benzoxazole-2-carbonitriles using Appel's salt.^a

^aReagents and conditions: Method A: 1. pyridine, RT, 1 h; 2. 100 °C, 1–3 h, 21% for 1, 59% for 2, 14% for 8, 53% for 9, 34% for 16, 56% for 18, 30% for 19; Method B: 1. THF, RT, 1 h; 2. DMSO, 100 °C, 1 h, 16% for 10, 5% for 11, 19% for 13; Method C: THF, 140 °C, 20 min (MW), 5% for 12.

The corresponding 2-aminophenol derivative and Appel's salt were stirred in pyridine at room temperature for 1 h to form the intermediate and then the mixture was heated to 100 °C for 1–3 h, depending on the starting compound (Method A, see main text).

This general method A was used in the majority of cases. Nevertheless, in some cases, these conditions resulted in a significant amount of by-products and inability to adequately purify the final products. Alternatively, the intermediate was formed in THF, and then evaporated, dissolved in DMSO and stirred at 100 °C for 1 h (Method B, see main text). Despite rather poor yields, this method was useful for the synthesis of hydroxy-substituted benzoxazole-2-carbonitriles (**10**, **11**, and **13**). 6-Hydroxy-substituted benzoxazole-2-carbonitrile (**12**) was synthesized according to Woodrofe et al. [3]. The reaction was carried-out in THF under microwave irradiation at 140 °C for 20 min. (Method C, see main text).

The above methods were effective to produce most of the 2-carbonitrile-substituted benzoxazoles. However, we could not synthesize the 5-methoxy derivative (**7**) and the 5-nitro derivative (**17**) using Appel's salt, so an alternative synthetic procedure was required. This synthetic route was inspired by Möller [4]. The corresponding 2-aminophenol derivatives were converted to 1,3-benzoxazole-2-thiols using CS₂ and KOH in an EtOH-H₂O mixture. Thiols (**VIII**, **IX**) were refluxed in thionyl chloride in the presence of DMF as catalyst to afford 2-chloro-substituted benzoxazoles in 1 h. The latter were subjected to an aromatic nucleophilic substitution reaction with KCN, requiring different temperatures and reaction times were needed, depending on the chloro-derivative (Scheme S3).




Scheme S3. Alternative method of the synthesis of benzoxazole-2-carbonitriles^a

^aReagents and conditions: (a) CS₂, KOH, EtOH/H₂O, reflux, 4–7 h, 83% for **VIII**, 63% for **IX**; (b) SOCl₂, cat. DMF, reflux, 1 h; (c) KCN, DMF, various temperatures and reaction times, 41% for **7**, 63% for **17** (yields after two consecutive steps).

The preparation of methyl-substituted benzoxazole-2-carbonitriles led to unexpected problems. While the 6-methyl derivative **5** was synthesized according to Method A without a problem, the 4-methyl- and 5-methyl-substituted benzoxazoles could not be isolated. Several methods were used for these syntheses, and the formation of these compounds was observed in reasonable amounts in the reaction mixtures. However, a considerable part of the products was lost during the workup and, moreover, we observed their significant decomposition within one hour, even at –78 °C. In the case of the 7-methyl derivative, the situation was similar, with an even higher decomposition rate that started during workup process.

Once the hydroxy- (**10–13**) and the nitro-substituted products (**16–19**) were available, further analogues were prepared from them to expand our library (Scheme S4). Compounds **10** and **11** were converted to *O*-acetyl derivatives **14** and **15**, respectively, using acetic anhydride in MeCN and concentrated H₂SO₄ served as catalyst.

The nitro-compounds were reduced with tin(II)chloride dihydrate in EtOAc with reactions proceeding to completion at 70 °C for 2 h. The obtained amines (**20**, **21**, **22**, and **23**) were acylated with benzoic anhydride in Et₃N-DMF solution mixture and a catalytic amount of DMAP to yield compounds **24–27**.




Scheme S4. Synthesis of further benzoxazole-2-carbonitrile derivatives^a

^aReagents and conditions: (a) Ac₂O, conc. H₂SO₄, MeCN, 60 °C, 1 h, 24% for **14**, 25% for **15**; (b) SnCl₂ × 2H₂O, EtOAc, 70 °C, 2 h, 52% for **20**, 63% for **21**, 66% for **22**, 68% for **23**; (c) (PhCO)₂O, DMAP, Et₃N, DMF, various temperatures and reaction times, 41% for **24**, 68% for **25**, 55% for **26**, 60% for **27**.

1.2. Preparation of vinylthiazole-linked boronic acid derivative

First, 2-(2-bromothiazol-4-yl)acetic acid (**XXIII**) was reacted with thionyl chloride in MeOH to give the methyl ester **XXIV** in excellent yield. The bromine of the ester was converted to vinyl in a reaction with tributyl(vinyl)tin to give the compound **XXV** in moderate yield. Subsequently, the ester group was hydrolyzed in the presence of NaOH to afford the carboxylic acid **XXVI**, which could acylate (*R*)-BoroLeu(+)-pinanediol trifluoroacetate in the presence of HATU, leading to compound **28** (Scheme S5).




Scheme S5. Synthesis of compound **28**^a

^aReagents and conditions: (a) SOCl₂, MeOH, RT, overnight, 95%, (b) Bu₃(vinyl)Sn, Pd(PPh₃)₂Cl₂, THF, 100 °C, 2 h, 40%, (c) NaOH, MeOH-H₂O, RT, 5 h, 99%, (d) (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate, HATU, DIPEA, DMF, RT, overnight, 9%.

1.3. Preparation of benzimidazole-2-carbonitrile-linked boronic acids

The synthetic strategy was to attach the boronic acid moiety to the nitrogen atom of benzimidazole-2-carbonitrile via an alkyl linker (Scheme S6). The molecules were synthesized with methylene, ethylene, propylene and *n*-butylene linkers. First, benzimidazole-2-carbonitrile had to be synthesized as a key intermediate. Therefore, *o*-phenylenediamine (**XXVII**) was reacted with methyl 2,2,2-trichloroacetimidate to give the 2-trichloromethyl-benzimidazole (**XXVIII**), which was stirred in 7 M NH₃ solution in MeOH to obtain the carbonitrile derivative **XXIX**. This compound was *N*-alkylated with four different ω -bromoalkyl esters to introduce the linker. In all cases DMF was used as a solvent and DIPEA served as base. However, different temperatures and reaction times were required to achieve complete conversions (see data alongside the characterization of the intermediates below). The resulting *N*-alkylated compounds were not isolated but immediately subjected to ester hydrolysis in a one-pot reaction. Depending on the substrate, LiOH \times H₂O or K₂CO₃ was used for the hydrolysis. In general, two competing reactions took place: the desired hydrolysis of the ester functional group and the undesired hydrolysis of the carbonitrile functional group. The latter was the main reason for the low yields. The resulting free carboxylic acids (**XXX**, **XXXI**, **XXXII** and **XXXIII**) were activated with HATU and coupled to (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate with good yields. Three different methods were used to deprotect the boronic acids. Compound **33** was obtained by an oxidative cleavage using NaIO₄ and NH₄OAc in an acetone-H₂O solvent mixture, compounds **34** and **36** were obtained by a biphasic transesterification reaction using isobutylboronic acid in a MeOH-HCl-*n*-hexane solvent mixture, while **35** was prepared by a different transesterification method. Namely, it was reacted with boric acid in a (*i*Pr)₂O-HCl solvent mixture (Scheme S6).




Scheme S6. Synthesis of benzimidazole-2-carbonitrile containing boronic acid derivatives^a

^aReagents and conditions: (a) methyl 2,2,2-trichloroacetimidate, AcOH, RT, 1 h, 88%; (b) NH₃, MeOH, RT, 4 h, 60%; (c) various ω-bromoalkyl esters, DIPEA, DMF, various temperatures and reaction times; (d) LiOH × H₂O, DMF/THF/H₂O, RT, 4 h, 49% for **XXX**; (e) K₂CO₃, DMF/THF/H₂O, RT, 16 h, 24% for **XXXI**, 25% for **XXXII**, 28% for **XXXIII** (yields of two consecutive steps); (f) (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate, HATU, DIPEA, DMF, RT, 2 h, 80% for **29**, 72% for **30**, 82% for **31**, 83% for **32**; (g) NaIO₄, NH₄OAc, acetone/H₂O, RT, 16 h, 49% for **33**; (h) isobutylboronic acid, MeOH/HCl/*n*-hexane, RT, 16 h, 51% for **34**, 63% for **36**; (i) B(OH)₃, (iPr)₂O/HCl, RT, 16 h, 43% for **35**.

1.4. Preparation of chloro-substituted benzimidazole-2-carbonitrile-linked boronic acids

As starting materials, appropriately chloro-substituted *o*-fluoronitrobenzenes [4-chloro-2-fluoronitrobenzene (**XXXIV**) and 1-chloro-2-fluoro-3-nitrobenzene (**XXXV**)] were used (Scheme S7). Aromatic nucleophilic substitution reactions were carried-out with ethyl 3-aminopropanoate hydrochloride and DIPEA was used to release the amine and neutralize the HF from the reaction. Hydrolysis of the ethyl esters was carried out in a one-pot reaction with NaOH in a DMF/THF/H₂O solvent mixture at 70 °C. Acids **XXXVI** and **XXXVII** were coupled to (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate using the same method as mentioned previously. Then, the reduction of the nitro group was carried out with SnCl₂ × 2H₂O in EtOAc, and the reaction proceeded overnight at 70 °C to achieve complete conversion. To obtain the designed carbonitriles **37** and **38**, diamines **XL** and **XLI** were reacted with Appel's salt in pyridine (Scheme S7). Interestingly, the formation of **37** was significantly faster than that of **38**.




Scheme S7. Synthesis of chloro-substituted derivatives of **30**^a

^aReagents and conditions: (a) ethyl 3-aminopropanoate hydrochloride, DIPEA, DMF, RT, 16 h; (b) NaOH, DMF/THF/H₂O, 70 °C, 2 h, 88% for **XXXVI**, 74% for **XXXVII** (yields of two consecutive steps); (c) (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate, HATU, DIPEA, DMF, RT, 2 h, 92% for **XXXVIII**, 84% for **XXXIX**; (d) SnCl₂ × 2H₂O, EtOAc, 70 °C, 16 h, 84% for **XL**, 88% for **XLI**; (e) Appel's salt, pyridine, RT, 1 h, then 50 °C, 3 h, 42% for **37**; (f) Appel's salt, pyridine, RT, 1 h, then 70 °C, 6 h, 34% for **38**.

1.5. Preparation of benzoxazole-2-carbonitrile-linked boronic acids

Two compounds were synthesized with linkers of different lengths connecting the Thr and Cys targeting units. The synthetic routes are shown in Schemes S8 and S9. Alkaline hydrolysis of methyl 2-(3-amino-4-hydroxyphenyl)acetate (**XLII**) led to a large number of side products, whereas acid-catalyzed hydrolysis gave much better results. The hydrochloride salt of 2-(3-amino-4-hydroxyphenyl)acetic acid (**XLIII**) was obtained almost in quantitative yield. It was then coupled with (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate by the usual method. The amide **XLIV** was converted to the benzoxazole-2-carbonitrile derivative **39** in a reaction with Appel's salt (Scheme S8). Hydrolysis of the pinanediol ester was carried out with the biphasic transesterification reaction to give the boronic acid **40**.




Scheme S8. Synthesis of benzoxazole-2-carbonitrile containing boronic acid derivative^a

^aReagents and conditions: (a) 20% HCl, reflux, 3 h, 98%; (b) (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate, HATU, DIPEA, DMF, RT, 2 h, 51%; (c) Appel's salt, pyridine, RT, 1 h, then 90 °C, 1 h, 23%; (d) isobutylboronic acid, MeOH/HCl/*n*-hexane, RT, 16 h, 80%.

2. Synthesized compounds


2.1. Synthesis of intermediates for the benzoxazole-2-carbonitrile library

2-Aminobenzene-1,4-diol (II)



To a solution of 2-nitrobenzene-1,4-diol (I, 264 mg, 1.70 mmol) in EtOH (20 mL), 10% Pd/C (Selcat Q6, 26 mg) was added. The reactor was filled with H₂ (8 bar) and the mixture was allowed to stir at room temperature for 2 h. It was then filtered through a pad of Celite, washed with EtOH (2 × 20 mL) and the volatiles evaporated. The product 2-aminobenzene-1,4-diol (II) was obtained as a brown solid (210 mg, 99% yield). Physical and spectroscopic data were identical to those reported previously [5].


3-Nitrobenzene-1,2-diol (IV)



Catechol (III, 10.0 g, 90.9 mmol) was dissolved in Et₂O (500 mL) and the solution was cooled to 0 °C in an ice bath. Fuming HNO₃ (4.0 mL) was added dropwise in 2 h, then the reaction mixture was allowed to warm to room temperature where it was stirred for 16 h. The mixture was extracted with H₂O (3 ×


150 mL), followed by evaporation of the volatiles. The residue was triturated with *n*-hexane (300 mL), heated to boiling and then filtered. The mother liquor was concentrated and the trituration process was repeated once more. The product 3-nitrobenzene-1,2-diol (**IV**) was obtained as a yellow solid (1343 mg, 10% yield). Physical and spectroscopic data were identical to those reported previously [1].

3-Aminobenzene-1,2-diol (**VII**)




To a solution of 3-nitrobenzene-1,2-diol (**IV**, 151 mg, 0.97 mmol) in MeOH (10 mL), 10% Pd/C (Selcat Q6, 15 mg) was added. The mixture was hydrogenated at atmospheric pressure at room temperature for 4 h. It was then filtered through a pad of Celite, washed with MeOH (2 × 20 mL) and the volatiles evaporated. The product 3-aminobenzene-1,2-diol (**VII**) was obtained as a brown solid (119 mg, 98% yield). Physical and spectroscopic data were identical to those reported previously [6].

5-Methoxy-1,3-benzoxazole-2-thiol (**VIII**)



To a solution of 2-amino-4-methoxyphenol (**XIX**, 415 mg, 2.98 mmol, 1.0 equiv.) in EtOH (15 mL) and H₂O (3 mL), CS₂ (180 μL, 2.98 mmol, 1.0 equiv.) and KOH (167 mg, 2.98 mmol, 1.0 equiv.) were added. The reaction mixture was allowed to reflux for 4 h, then it was cooled to room temperature, diluted with H₂O (60 mL), and the pH was adjusted to 1 with 10% HCl. The precipitate formed was filtered off and washed with H₂O (2 × 30 mL). The product 5-methoxy-1,3-benzoxazole-2-thiol (**VIII**) was obtained as a brown solid (449 mg, 83% yield). Mp.: 196–200 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 13.75 (s, 1H), 7.39 (d, *J* = 8.9 Hz, 1H), 6.80 (dd, *J* = 8.9, 2.5 Hz, 1H), 6.75 (d, *J* = 2.3 Hz, 1H), 3.77 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 180.59, 157.16, 142.39, 131.93, 110.37, 109.98, 95.60, 55.86; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₈H₆NO₂S: 180.0124, found: 180.0107; Purity by HPLC: 99%

5-Nitro-1,3-benzoxazole-2-thiol (**IX**)




To a solution of 2-amino-4-nitrophenol (**XX**, 1064 mg, 6.90 mmol, 1.0 equiv.) in EtOH (31 mL) and H₂O (7 mL) CS₂ (417 μL, 6.90 mmol, 1.0 equiv.) and KOH (387 mg, 6.90 mmol, 1.0 equiv.) were added. The reaction mixture was allowed to reflux for 7 h, then it was cooled to room temperature, diluted with H₂O (90 mL), and the pH was adjusted to 1 with 10% HCl. The precipitate formed was filtered off and washed with H₂O (2 × 30 mL). The 5-nitro-1,3-benzoxazole-2-thiol (**IX**) was obtained as a yellow solid (891 mg, 66% yield). Mp.: 231–235 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.17 (dd, *J* = 8.9, 2.3 Hz, 1H), 7.92 (d, *J* = 2.3 Hz, 1H), 7.71 (d, *J* = 8.9 Hz, 1H); ¹³C NMR (126 MHz, DMSO-*d*₆) 181.42, 151.96, 144.66, 132.22,

120.01, 110.29, 105.67; HRMS (APCI⁻) *m/z* [M-H]⁻, calcd. for C₇H₃N₂O₃S: 194.9869, found: 194.9855; Purity by HPLC: 99%


2.2. Synthesis of benzoxazole-2-carbonitriles

6-Methyl-1,3-benzoxazole-2-carbonitrile (5)




The reaction was carried out according to Method A, starting from 6-amino-*m*-cresol (**X**, 74 mg, 0.60 mmol) and Appel's salt (138 mg, 0.66 mmol). Reagents were stirred in pyridine (3.6 mL) at room temperature for 1 h, then the mixture was heated to 100 °C for 1 h. After workup, compound **5** (20 mg, 21% yield) was isolated as a dark brown solid. Mp.: 54–55 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.85 (d, *J* = 8.3 Hz, 1H), 7.74 (s, 1H), 7.42 (d, *J* = 8.2 Hz, 1H), 2.51 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 150.22, 140.12, 136.68, 136.51, 128.08, 120.82, 111.56, 109.78, 21.37; Purity by HPLC: 99%. HRMS measurements (ESI⁺, ESI⁻, APCI⁺ and APCI⁻) were done, but the compound was not ionizable.

4-Methoxy-1,3-benzoxazole-2-carbonitrile (6)



The reaction was carried out according to Method A, starting from 2-amino-3-methoxyphenol hydrochloride (**XI**, 176 mg, 1.0 mmol) and Appel's salt (229 mg, 1.1 mmol). Reagents were stirred in pyridine (6 mL) at room temperature for 1 h, then the mixture was heated to 100 °C for 2 h. After workup, compound **6** (103 mg, 59% yield) was isolated as a brown solid. Mp.: 54–57 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.62 (t, *J* = 8.3 Hz, 1H), 7.44 (d, *J* = 8.3 Hz, 1H), 7.11 (d, *J* = 8.2 Hz, 1H), 4.01 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 151.97, 151.25, 135.65, 130.35, 128.78, 109.68, 108.04, 103.74, 56.46; Purity by HPLC: 98%. HRMS measurements (ESI⁺, ESI⁻, APCI⁺ and APCI⁻) were done, but the compound was not ionizable.

5-Methoxy-1,3-benzoxazole-2-carbonitrile (7)




5-Methoxy-1,3-benzoxazole-2-thiol (**VIII**, 181 mg, 1.0 mmol) was charged in a flask, followed by a dropwise addition of SOCl₂ (6 mL) and DMF (one drop). The reaction mixture was allowed to reflux for 1 h, the volatiles were then removed under reduced pressure and the crude 2-chloro-5-methoxy-1,3-benzoxazole was used in the next step without further purification.

To a solution of the obtained 2-chloro-5-methoxy-1,3-benzoxazole in DMF (8 mL), KCN (91 mg, 1.4 mmol, 1.4 equiv.) was added. The reaction mixture was allowed to stir at 80 °C for 1 h. After the reaction was complete, it was diluted with H₂O (30 mL) and extracted with DCM (3 × 30 mL). The volatiles were removed under reduced pressure and the crude residue was purified by reversed-phase


flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 5-methoxy-1,3-benzoxazole-2-carbonitrile (**7**) was obtained as a brown solid (71 mg, 41% yield). Mp.: 66–70 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.81 (d, *J* = 9.1 Hz, 1H), 7.48 (d, *J* = 2.5 Hz, 1H), 7.27 (dd, *J* = 9.1, 2.6 Hz, 1H), 3.84 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 158.31, 144.58, 139.83, 137.44, 118.77, 112.22, 109.67, 103.17, 56.02; Purity by HPLC: 99%. HRMS measurements (ESI⁺, ESI⁻, APCI⁺ and APCI⁻) were done, but the compound was not ionizable.

6-Methoxy-1,3-benzoxazole-2-carbonitrile (**8**)




The reaction was carried out according to Method A, starting from 2-amino-5-methoxyphenol (**XII**, 139 mg, 1.0 mmol) and Appel's salt (229 mg, 1.1 mmol). Reagents were stirred in pyridine (6 mL) at room temperature for 1 h, then the mixture was heated to 100 °C for 2 h. After workup, compound **8** (25 mg, 14% yield) was isolated as a brown solid. Mp.: 68–72 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.84 (d, *J* = 8.6 Hz, 1H), 7.53 – 7.50 (m, 1H), 7.20 – 7.15 (m, 1H), 3.87 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 161.04, 151.47, 135.84, 132.43, 121.73, 116.34, 109.85, 95.63, 56.30; HRMS (APCI⁺) *m/z* [M+H]⁺, calcd. for C₉H₇N₂O₂: 175.0502, found: 175.0504; Purity by HPLC: 99%

7-Methoxy-1,3-benzoxazole-2-carbonitrile (**9**)




The reaction was carried out according to Method A, starting from 2-amino-6-methoxyphenol (**XIII**, 139 mg, 1.0 mmol) and Appel's salt (229 mg, 1.1 mmol). Reagents were stirred in pyridine (6 mL) at room temperature for 1 h, then the mixture was heated to 100 °C for 2 h. After workup, compound **9** (93 mg, 53% yield) was isolated as a light brown solid. Mp.: 86–90 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.52 – 7.49 (m, 2H), 7.32 – 7.27 (m, 1H), 4.00 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 144.74, 140.38, 139.33, 136.91, 127.35, 112.98, 111.33, 109.52, 56.50; HRMS (APCI⁺) *m/z* [M+H]⁺, calcd. for C₉H₇N₂O₂: 175.0502, found: 175.0501; Purity by HPLC: 100%

4-Hydroxy-1,3-benzoxazole-2-carbonitrile (**10**)




The reaction was carried out according to Method B, starting from 2-aminobenzene-1,3-diol (**XIV**, 75 mg, 0.6 mmol) and Appel's salt (125 mg, 0.6 mmol). After workup, compound **10** (15 mg, 16% yield) was isolated as a brown solid. Mp.: 107–111 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 10.99 (s, 1H), 7.47 (t, *J* = 8.2 Hz, 1H), 7.27 (d, *J* = 8.4 Hz, 1H), 6.92 (d, *J* = 7.9 Hz, 1H); ¹³C NMR (126 MHz, DMSO-*d*₆) 151.55, 150.77, 135.17, 130.17, 128.39, 111.46, 109.83, 101.79; HRMS (APCI⁻) *m/z* [M-H]⁻, calcd. for C₈H₃N₂O₂: 159.0189, found: 159.0194; Purity by HPLC: 97%

5-Hydroxy-1,3-benzoxazole-2-carbonitrile (**11**)




The reaction was carried out according to Method B, starting from 2-aminobenzene-1,4-diol (**II**, 63 mg, 0.5 mmol) and Appel's salt (104 mg, 0.5 mmol). After workup, compound **11** (4 mg, 5% yield) was isolated as a brown solid. Mp.: 140–145 °C; ¹H NMR (300 MHz, DMSO-*d*₆) 10.01 (s, 1H), 7.73 (d, *J* = 9.1 Hz, 1H), 7.20 (s, 1H), 7.14 (d, *J* = 8.9 Hz, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) 156.42, 143.82, 139.88, 137.32, 118.57, 112.09, 109.83, 105.12; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₈H₅N₂O₂: 159.0189, found: 159.0198; Purity by HPLC: 100%

6-Hydroxy-1,3-benzoxazole-2-carbonitrile (**12**)




The reaction was carried out according to Method C, starting from 4-aminobenzene-1,3-diol (**XV**, 125 mg, 1.0 mmol) and Appel's salt (209 mg, 1.0 mmol). After workup, compound **12** (8 mg, 5% yield) was isolated as a brown solid. Mp.: 135–140 °C; ¹H NMR (300 MHz, DMSO-*d*₆) 10.52 (s, 1H), 7.77 (d, *J* = 8.8 Hz, 1H), 7.17 (s, 1H), 7.04 (d, *J* = 7.2 Hz, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) 159.52, 151.45, 135.21, 131.43, 121.85, 116.39, 109.98, 97.23; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₈H₅N₂O₂: 159.0189, found: 159.0196; Purity by HPLC: 100%

7-Hydroxy-1,3-benzoxazole-2-carbonitrile (**13**)



The reaction was carried out according to Method B, starting from 3-aminobenzene-1,2-diol (**VII**, 63 mg, 0.5 mmol) and Appel's salt (104 mg, 0.5 mmol). After workup, compound **13** (15 mg, 19% yield) was isolated as a brown solid. Mp.: 115–116 °C; ¹H NMR (300 MHz, DMSO-*d*₆) 10.51 (s, 1H), 7.37 (d, *J* = 4.6 Hz, 4H), 7.13 – 7.06 (m, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) 142.93, 140.72, 139.22, 136.77, 127.29, 114.85, 111.35, 109.78; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₈H₅N₂O₂: 159.0189, found: 159.0196; Purity by HPLC: 96%


2-Cyano-1,3-benzoxazol-4-yl acetate (**14**)



The reaction was carried out according to general *O*-acylation procedure, starting from 4-hydroxy-1,3-benzoxazole-2-carbonitrile (**6**, 17 mg, 0.10 mmol) and acetic anhydride (30 μL, 0.31 mmol). After


workup, compound **14** (5 mg, 24% yield) was isolated as a brown solid. Mp.: 65 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.85 (dd, *J* = 7.5, 6.9 Hz, 1H), 7.73 (t, *J* = 8.2 Hz, 1H), 7.44 – 7.40 (m, 1H), 2.41 (s, 3H); ¹³C NMR (75 MHz, DMSO-*d*₆) 168.36, 150.99, 142.17, 132.13, 129.73, 129.63, 119.54, 109.81, 109.46, 20.46; Purity by HPLC: 98%. HRMS measurements (ESI⁺, ESI⁻, APCI⁺ and APCI⁻) were done, but the compound was not ionizable.

2-Cyano-1,3-benzoxazol-5-yl acetate (**15**)




The reaction was carried out according to general *O*-acylation procedure, starting from 5-hydroxy-1,3-benzoxazole-2-carbonitrile (**11**, 13 mg, 0.08 mmol) and acetic anhydride (23 μL, 0.24 mmol). After workup, compound **15** (4 mg, 25% yield) was isolated as a brown solid. Mp.: 58 °C; ¹H NMR (300 MHz, DMSO-*d*₆) 7.99 (d, *J* = 9.0 Hz, 1H), 7.83 (d, *J* = 2.0 Hz, 1H), 7.49 (dd, *J* = 9.0, 2.1 Hz, 1H), 2.31 (s, 3H); ¹³C NMR (75 MHz, DMSO-*d*₆) 169.31, 148.69, 147.58, 143.17, 139.34, 138.39, 123.84, 114.61, 112.39, 20.81; Purity by HPLC: 100%. HRMS measurements (ESI⁺, ESI⁻, APCI⁺ and APCI⁻) were done, but the compound was not ionizable.

4-Nitro-1,3-benzoxazole-2-carbonitrile (**16**)



The reaction was carried out according to Method A, starting from 2-amino-3-nitrophenol (**XVI**, 339 mg, 2.2 mmol) and Appel's salt (505 mg, 2.4 mmol). Reagents were stirred in pyridine (13.2 mL) at room temperature for 1 h, then the mixture was heated to 100 °C for 3 h. After workup, compound **16** (140 mg, 34% yield) was isolated as a brown solid. Mp.: 92–95 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.47 – 8.40 (m, 2H), 7.94 (t, *J* = 8.3 Hz, 1H); ¹³C NMR (126 MHz, DMSO-*d*₆) 151.20, 140.00, 132.81, 129.22, 122.84, 118.93, 109.21; HRMS (APCI⁻) *m/z* [M-H]⁻, calcd. for C₈H₅N₃O₃: 189.0179, found: 189.0151; Purity by HPLC: 99%

5-Nitro-1,3-benzoxazole-2-carbonitrile (**17**)




5-Nitro-1,3-benzoxazole-2-thiol (**IX**, 196 mg, 1.0 mmol, 1.0 equiv.) was charged in a flask, followed by a dropwise addition of SOCl₂ (6 mL) and DMF (one drop). The reaction mixture was allowed to reflux for 1 h, the volatiles were then removed under reduced pressure and the crude 2-chloro-5-nitro-1,3-benzoxazole was used in the next step without further purification.

To a solution of the obtained 2-chloro-5-nitro-1,3-benzoxazole in DMF (8 mL), KCN (91 mg, 1.4 mmol, 1.4 equiv.) was added. The reaction mixture was allowed to stir at room temperature for 3 h. After the reaction was complete, it was diluted with H₂O (30 mL) and extracted with DCM (3 × 30 mL). The


volatiles were removed under reduced pressure and the crude residue was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 5-nitro-1,3-benzoxazole-2-carbonitrile (**17**) was obtained as a brown solid (118 mg, 63% yield). Mp.: 110–112 °C; ¹H NMR (300 MHz, DMSO-*d*₆) 8.93 (s, 1H), 8.56 (d, *J* = 8.2 Hz, 1H), 8.22 (d, *J* = 9.1 Hz, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) 153.14, 146.16, 140.14, 139.13, 124.59, 117.89, 113.05, 109.24; HRMS (APCI⁻) *m/z* [M-H]⁻, calcd. for C₈H₃N₃O₃: 189.0179, found: 189.0175; Purity by HPLC: 100%

6-Nitro-1,3-benzoxazole-2-carbonitrile (**18**)




The reaction was carried out according to Method A, starting from 5-nitro-2-amino-phenol (**XVII**, 170 mg, 1.1 mmol) and Appel's salt (252 mg, 1.2 mmol). Reagents were stirred in pyridine (6.6 mL) at room temperature for 1 h, then the mixture was heated to 100 °C for 1 h. After workup, compound **18** (117 mg, 56% yield) was isolated as a brown solid. Mp.: 56 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.95 (d, *J* = 2.1 Hz, 1H), 8.43 (dd, *J* = 8.9, 2.1 Hz, 1H), 8.24 (d, *J* = 8.9 Hz, 1H); ¹³C NMR (126 MHz, DMSO-*d*₆) 149.65, 147.85, 143.95, 141.66, 122.69, 122.40, 109.66, 109.35; HRMS (APCI⁻) *m/z* [M-H]⁻, calcd. for C₈H₃N₃O₃: 189.0179, found: 189.0154; Purity by HPLC: 99%

7-Nitro-1,3-benzoxazole-2-carbonitrile (**19**)



The reaction was carried out according to Method A, starting from 2-amino-6-nitrophenol (**XVIII**, 123 mg, 0.8 mmol) and Appel's salt (184 mg, 0.88 mmol). Reagents were stirred in pyridine (4.8 mL) at room temperature for 1 h, then the mixture was heated to 100 °C for 3 h. After workup, compound **19** (46 mg, 30% yield) was isolated as a brown solid. Mp.: 111–114 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.53 (d, *J* = 8.2 Hz, 1H), 8.49 (d, *J* = 8.1 Hz, 1H), 7.84 (t, *J* = 8.2 Hz, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆) 142.73, 141.82, 139.04, 133.32, 129.08, 126.99, 124.98, 109.16; HRMS (APCI⁻) *m/z* [M-H]⁻, calcd. for C₈H₃N₃O₃: 189.0179, found: 189.0155; Purity by HPLC: 100%


4-Amino-1,3-benzoxazole-2-carbonitrile (**20**)



The reaction was carried out according to general nitro reduction procedure, starting from 4-nitro-1,3-benzoxazole-2-carbonitrile (**16**, 227 mg, 1.20 mmol) and SnCl₂ × 2H₂O (1.62 g, 7.2 mmol). After workup, compound **20** (99 mg, 52% yield) was isolated as a yellow solid. Mp.: 80–84 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.31 (t, *J* = 8.1 Hz, 1H), 6.87 (d, *J* = 8.1 Hz, 1H), 6.63 (d, *J* = 8.1 Hz, 1H), 6.19 (s, 2H); ¹³C


NMR (126 MHz, DMSO-*d*₆) 151.84, 143.01, 134.25, 130.82, 126.92, 110.53, 109.01, 97.54; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₈H₄N₃O: 158.0359, found: 158.0336; Purity by HPLC: 98%

5-Amino-1,3-benzoxazole-2-carbonitrile (**21**)




The reaction was carried out according to general nitro reduction procedure, starting from 5-nitro-1,3-benzoxazole-2-carbonitrile (**17**, 102 mg, 0.54 mmol) and SnCl₂ × 2H₂O (731 mg, 3.24 mmol). After workup, compound **21** (54 mg, 63% yield) was isolated as a yellow solid. Mp.: 169–173 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.54 (d, *J* = 8.9 Hz, 1H), 6.94 (dd, *J* = 6.4, 2.5 Hz, 1H), 6.92 (d, *J* = 2.0 Hz, 1H), 5.43 (s, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 148.31, 142.42, 140.06, 136.39, 117.73, 111.51, 109.95, 101.90. HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₈H₄N₃O: 158.0359, found: 158.0340; Purity by HPLC: 100%

6-Amino-1,3-benzoxazole-2-carbonitrile (**22**)




The reaction was carried out according to general nitro reduction procedure, starting from 6-nitro-1,3-benzoxazole-2-carbonitrile (**18**, 76 mg, 0.40 mmol) and SnCl₂ × 2H₂O (542 mg, 2.4 mmol). After workup, compound **22** (42 mg, 66% yield) was isolated as a yellow solid. Mp.: 157 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.55 (d, *J* = 8.7 Hz, 1H), 6.83 (dd, *J* = 8.8, 1.9 Hz, 1H), 6.79 (d, *J* = 1.8 Hz, 1H), 6.02 (s, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 152.37, 151.58, 132.96, 128.77, 121.48, 115.27, 110.38, 92.88; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₈H₄N₃O: 158.0359, found: 158.0339; Purity by HPLC: 95%

7-Amino-1,3-benzoxazole-2-carbonitrile (**23**)




The reaction was carried out according to general nitro reduction procedure, starting from 7-nitro-1,3-benzoxazole-2-carbonitrile (**19**, 31 mg, 0.18 mmol) and SnCl₂ × 2H₂O (237 mg, 1.05 mmol). After workup, compound **23** (19 mg, 68% yield) was isolated as a yellow solid. Mp.: 96–99 °C; ¹H NMR (300 MHz, DMSO-*d*₆) 7.25 (t, *J* = 6.8 Hz, 1H), 7.05 (d, *J* = 8.0 Hz, 1H), 6.83 (d, *J* = 7.0 Hz, 1H), 5.96 (s, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) 139.72, 138.72, 136.17, 134.25, 127.32, 112.46, 109.96, 107.26; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₈H₄N₃O: 158.0359, found: 158.0342; Purity by HPLC: 98%

N-(2-cyano-1,3-benzoxazol-4-yl)benzamide (**24**)




The reaction was carried out according to general *N*-acylation procedure, starting from 4-amino-1,3-benzoxazole-2-carbonitrile (**20**, 18 mg, 0.11 mmol), benzoic anhydride (75 mg, 0.33 mmol), DMAP (1.3 mg, 0.011 mmol) and Et₃N (46 μL, 0.33 mmol). Reagents were stirred in DMF (2 mL) at 120 °C for 48 h and after workup, compound **24** (12 mg, 41% yield) was isolated as a white solid. Mp.: 148–151 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 10.63 (s, 1H), 8.05 – 8.01 (m, 2H), 7.97 (dd, *J* = 6.7, 2.1 Hz, 1H), 7.74 – 7.69 (m, 2H), 7.64 (t, *J* = 7.3 Hz, 1H), 7.57 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 166.25, 150.95, 136.64, 134.33, 132.90, 132.52, 132.06, 130.03, 128.92, 128.42, 120.27, 110.13, 108.29; HRMS (APCI⁻) *m/z* [M-H]⁻, calcd. for C₁₅H₈N₃O₂: 262.0622, found: 262.0588; Purity by HPLC: 100%

***N*-(2-cyano-1,3-benzoxazol-5-yl)benzamide (25)**



The reaction was carried out according to general *N*-acylation procedure, starting from 5-amino-1,3-benzoxazole-2-carbonitrile (**21**, 40 mg, 0.25 mmol), benzoic anhydride (170 mg, 0.75 mmol), DMAP (3.1 mg, 0.025 mmol) and Et₃N (105 μL, 0.75 mmol). Reagents were stirred in DMF (2 mL) at room temperature for 5 h and after workup, compound **25** (45 mg, 68% yield) was isolated as a white solid. Mp.: 187–188 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 10.55 (s, 1H), 8.46 (d, *J* = 1.8 Hz, 1H), 8.02 – 7.96 (m, 3H), 7.90 (d, *J* = 9.0 Hz, 1H), 7.62 (t, *J* = 7.3 Hz, 1H), 7.55 (t, *J* = 7.4 Hz, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 165.80, 146.21, 138.99, 137.90, 137.61, 134.52, 131.76, 128.41, 127.67, 122.64, 111.73, 111.68, 109.66; HRMS (APCI⁻) *m/z* [M-H]⁻, calcd. for C₁₅H₈N₃O₂: 262.0622, found: 262.0588; Purity by HPLC: 100%


***N*-(2-cyano-1,3-benzoxazol-6-yl)benzamide (26)**



The reaction was carried out according to general *N*-acylation procedure, starting from 6-amino-1,3-benzoxazole-2-carbonitrile (**22**, 20 mg, 0.13 mmol), benzoic anhydride (88 mg, 0.39 mmol), DMAP (1.5 mg, 0.013 mmol) and Et₃N (52 μL, 0.39 mmol). Reagents were stirred in DMF (2 mL) at room temperature for 16 h and after workup, compound **26** (18 mg, 55% yield) was isolated as a light-yellow solid. Mp.: 201–202 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 10.71 (s, 1H), 8.51 (d, *J* = 1.6 Hz, 1H), 8.03 – 7.94 (m, 3H), 7.88 (dd, *J* = 8.9, 1.8 Hz, 1H), 7.63 (t, *J* = 7.3 Hz, 1H), 7.56 (t, *J* = 7.5 Hz, 2H); ¹³C NMR (126 MHz,

DMSO-*d*₆) 166.04, 150.31, 140.52, 136.60, 134.48, 134.36, 131.93, 128.44, 127.75, 121.29, 119.74, 109.79, 102.21; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₁₅H₈N₃O₂: 262.0622, found: 262.0589; Purity by HPLC: 100%


***N*-(2-cyano-1,3-benzoxazol-7-yl)benzamide (27)**



The reaction was carried out according to general *N*-acylation procedure, starting from 7-amino-1,3-benzoxazole-2-carbonitrile (**23**, 15 mg, 0.095 mmol), benzoic anhydride (64 mg, 0.29 mmol), DMAP (1.2 mg, 0.0095 mmol) and Et₃N (40 μL, 0.29 mmol). Reagents were stirred in DMF (2 mL) at 100 °C for 5 h and after workup, compound **27** (15 mg, 60% yield) was isolated as a white solid. Mp.: 157–160 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 10.82 (s, 1H), 8.06 – 8.01 (m, 2H), 7.86 – 7.79 (m, 2H), 7.67 – 7.55 (m, 4H); ¹³C NMR (126 MHz, DMSO-*d*₆) 165.39, 143.41, 139.92, 136.87, 133.43, 132.15, 128.50, 127.96, 126.79, 123.70, 123.60, 117.96, 109.57; HRMS (APCI-) *m/z* [M-H]⁻, calcd. for C₁₅H₈N₃O₂: 262.0622, found: 262.0590; Purity by HPLC: 98%


2.3. Synthesis of boronic acid derivatives

Methyl 2-(2-bromo-1,3-thiazol-4-yl)acetate (XXIV)




In a round bottom flask, the commercially available 2-(2-bromothiazol-4-yl)acetic acid (**XXIII**, 244 mg, 1.1 mmol) was dissolved in MeOH (20 mL) at 0 °C. Thionyl chloride (235 μL, 3.3 mmol, 3.0 equiv) was added dropwise and the reaction mixture was stirred at room temperature overnight. The product was isolated as an orange solid after evaporation of the solvent (250 mg, 95% yield). Mp.: 91–93 °C; ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.52 (s, 1H), 7.48 (s, 1H) [duplication of signals], 3.72 (s, 3H), 3.69 (s, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) δ 171.52, 150.52, 122.12, 122.60, 36.96, 36.81; HRMS (ESI+) *m/z* [M+H]⁺, calcd. for C₆H₇NO₂SBr: 235.9380, found: 235.9379; Purity by HPLC: >95%

Methyl 2-(2-ethenyl-1,3-thiazol-4-yl)acetate (XXV)




In a sealed tube, **XXIV** (222 mg, 0.94 mmol) was dissolved in dry THF (10 mL), bis(triphenylphosphine)palladium(II) dichloride (66 mg, 0.094 mmol, 10%) was added, followed by tributyl(vinyl)tin (440 μ L, 1.5 mmol, 1.6 equiv.). The reaction mixture was heated to 100 °C and stirred for 2 h. The mixture was cooled and purified directly by flash column chromatography (*n*-hexane-EtOAc) to afford the product as a colourless oil (70 mg, 40% yield). ^1H NMR (500 MHz, CDCl_3) δ 7.11 (s, 1H), 7.10 (s, 1H) [duplication of signals], 6.89 (dd, $J = 17.5, 10.9$ Hz, 1H), 6.01 (d, $J = 17.5$ Hz, 1H), 5.53 (d, $J = 10.9$ Hz, 1H), 3.83 (s, 2H), 3.77 (s, 2H) [duplication of signals], 3.74 (s, 3H), 3.73 (s, 3H) [duplication of signals]; ^{13}C NMR (126 MHz, CDCl_3) δ 170.63, 170.10 [duplication of signals], 149.14, 147.66 [duplication of signals], 151.48, 130.37, 119.92, 118.29, 115.70, 52.23, 52.13 [duplication of signals], 36.73, 36.71 [duplication of signals]; Purity by HPLC: >95%

2-(2-Ethenyl-1,3-thiazol-4-yl)acetic acid (**XXVI**)



In a round bottom flask, **XXV** (44 mg, 0.24 mmol) was dissolved in MeOH (10 mL) and 1 M NaOH (1.0 mL) solution was added. The mixture was stirred at room temperature for 5 h until full conversion. After evaporation of the solvent, the crude was suspended in H_2O (15 mL) and the pH was set to 1 by 10% HCl. EtOAc (3×10 mL) was used to extract the product that was isolated after drying (MgSO_4) and evaporating the organic solvent to obtain a yellowish oil (40 mg, 99% yield). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 7.44 (s, 1H), 6.91 (dd, $J = 17.4, 10.9$ Hz, 1H), 6.01 (d, $J = 17.5$ Hz, 1H), 5.56 (d, $J = 10.9$ Hz, 1H), 3.82 (s, 2H); ^{13}C NMR (126 MHz, $\text{DMSO-}d_6$) δ 187.4, 144.5, 133.4, 122.6, 116.1, 108.2, 31.8; HRMS (ESI $^-$) m/z [M-H] $^-$, calcd. for $\text{C}_7\text{H}_6\text{NO}_2\text{S}$: 168.0119, found: 168.0125; Purity by HPLC: >95%


2-(2-Ethenyl-1,3-thiazol-4-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (**28**)



In a round bottom flask, **XXVI** (34 mg, 0.2 mmol) was dissolved in DMF (3.0 mL) under Ar atmosphere at room temperature. (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate (76 mg, 0.2 mmol, 1.0 equiv), HATU (84 mg, 0.22 mmol, 1.1 equiv), and DIPEA (77 μ L, 0.44 mmol, 2.2 equiv.) were added subsequently, followed by stirring the reaction mixture overnight at room temperature. The mixture was then purified directly by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H_2O) (gradient from 1:9 to 10:0) to give the product as a brownish oil (8 mg, 9% yield). ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 7.07 (d, $J = 9.5$ Hz, 1H), 6.87 (dd, $J =$


17.4, 10.9 Hz, 1H), 6.10 (d, $J = 17.5$ Hz, 1H), 5.59 (d, $J = 10.9$ Hz, 1H), 4.31 – 4.23 (m, 1H), 3.77 (s, 2H), 3.10 – 2.91 (m, 2H), 2.37 – 2.29 (m, 1H), 2.19 – 2.12 (m, 1H), 2.06 (d, $J = 11.1$ Hz, 1H), 2.02 (dd, $J = 10.8$, 5.4 Hz, 1H), 1.87 – 1.81 (m, 1H), 1.67 – 1.59 (m, 1H), 1.45 (dd, $J = 14.1$, 7.7 Hz, 2H), 1.41 (s, 6H), 0.91 (dd, $J = 10.6$, 6.2 Hz, 6H), 0.86 (s, 3H) ppm; ^{13}C NMR (126 MHz, DMSO- d_6) δ 176.22, 129.63, 120.48, 118.19, 115.96, 84.57, 51.85, 39.84, 38.17, 37.30, 36.17, 36.02, 35.81, 28.78, 27.24, 26.39, 25.98, 24.12, 23.12, 21.97 ppm; HRMS (ESI $^+$) m/z [M+H] $^+$, calcd. for $\text{C}_{22}\text{H}_{34}\text{N}_2\text{O}_3\text{SBr}$: 417.2383, found: 417.2393; Purity by HPLC: >95%

2-(Trichloromethyl)-1H-1,3-benzodiazole (XXVIII)




To a stirred solution of benzene-1,2-diamine (**XXVII**, 3785 mg, 35.00 mmol) in acetic acid (100 mL), methyl 2,2,2-trichloroacetimidate (4.33 mL, 35.00 mmol, 1.0 equiv.) was added dropwise. The mixture was allowed to stir at room temperature for 1 h. The white precipitate was filtered and washed with H_2O (3×40 mL). The product 2-(trichloromethyl)-1H-1,3-benzodiazole (**XXVIII**) was obtained as a white powder (7254 mg, 88% yield). Physical and spectroscopic data were identical to those reported previously [7].

1H-1,3-Benzodiazole-2-carbonitrile (XXIX)



2-(Trichloromethyl)-1H-1,3-benzodiazole (**XXVIII**, 7154 mg, 30.38 mmol) was dissolved in ammonia solution (7 M in MeOH, 350 mL) and the reaction mixture was allowed to stir at room temperature for 4 h. White precipitation was then observed and the resulting mixture was concentrated, re-dissolved in EtOAc (500 mL), and washed with H_2O (300 mL). The aqueous layer was washed with EtOAc (2×100 mL) and the combined organic layers were concentrated. The concentrate was suspended in Et $_2$ O (300 mL), sonicated for 15 min, and the mixture filtered. The product, 1H-1,3-benzodiazole-2-carbonitrile (**XXIX**), was obtained as a white powder (2880 mg, 60% yield). Physical and spectroscopic data were identical to those reported previously [7].


2-(2-Cyano-1H-1,3-benzodiazol-1-yl)acetic acid (XXX)



1H-1,3-Benzodiazole-2-carbonitrile (**XXIX**, 501 mg, 3.50 mmol, 1.0 equiv.) was dissolved in DMF (20 mL) and DIPEA (1219 μL , 7.00 mmol, 2.0 equiv.). Ethyl bromoacetate (426 μL , 4.20 mmol, 1.2 equiv.) was then added dropwise and the reaction mixture was stirred at room temperature for 1 h. After the reaction was complete, it was diluted with THF (30 mL) and H_2O (60 mL). LiOH \times H_2O (2.0 equiv.) was then added and the reaction mixture was allowed to stir at room temperature for 4 h. The mixture


was concentrated, the residue re-dissolved in H₂O (80 mL) and washed with EtOAc (100 mL). The aqueous layer was acidified to pH 1 with 1 M HCl and extracted with EtOAc (3 × 80 mL). The combined organic layers were dried (MgSO₄), filtered, and the volatiles were removed under reduced pressure. The crude residue was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 2-(2-cyano-1*H*-1,3-benzodiazol-1-yl)acetic acid (**XXX**) was obtained as a light yellow powder (344 mg, 49% yield). Mp.: 140–143 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.83 (t, *J* = 7.5 Hz, 2H), 7.52 (t, *J* = 7.8 Hz, 1H), 7.43 (t, *J* = 8.0 Hz, 1H), 5.39 (s, 2H), resonance for COOH missing; ¹³C NMR (126 MHz, DMSO-*d*₆) 168.55, 141.53, 134.55, 127.03, 126.39, 124.32, 120.74, 111.67, 111.28, 45.83; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₁₀H₈N₃O₂: 202.0617, found: 202,0617; Purity by HPLC: 99%.

2-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (29**)**




To a stirred solution of 2-(2-cyano-1*H*-1,3-benzodiazol-1-yl)acetic acid (**XXX**, 81 mg, 0.40 mmol, 1.0 equiv.), HATU (167 mg, 0.44 mmol, 1.1 equiv.) and DIPEA (153 μL, 0.88 mmol, 2.2 equiv.) in DMF (2.5 mL), (*R*)-BoroLeu-(+)-pinanediol trifluoroacetate (152 mg, 0.40 mmol, 1.0 equiv.) was added and the mixture was allowed to stir at room temperature for 2 h. The mixture was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The obtained viscous oil was triturated with Et₂O (20 mL) and concentrated. The product 2-(2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (**29**) was obtained as a white powder (144 mg, 80% yield). Mp.: 71–72 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.64 (d, *J* = 5.7 Hz, 1H), 7.82 (d, *J* = 8.2 Hz, 1H), 7.66 (d, *J* = 8.3 Hz, 1H), 7.50 (t, *J* = 7.7 Hz, 1H), 7.41 (t, *J* = 7.7 Hz, 1H), 5.14 (s, *J* = 6.2 Hz, 2H), 4.22 (dd, *J* = 8.7, 1.8 Hz, 1H), 3.00 (dt, *J* = 9.9, 5.9 Hz, 1H), 2.21 (dt, *J* = 21.8, 9.6 Hz, 1H), 1.98 (ddd, *J* = 10.6, 6.1, 4.5 Hz, 1H), 1.86 (t, *J* = 5.5 Hz, 1H), 1.77 (dd, *J* = 6.6, 4.2 Hz, 1H), 1.69 – 1.59 (m, 2H), 1.45 (ddd, *J* = 15.3, 9.6, 5.8 Hz, 1H), 1.31 (ddd, *J* = 7.8, 5.1, 1.8 Hz, 1H), 1.21 (s, *J* = 5.9 Hz, 6H), 1.09 (t, *J* = 8.1 Hz, 1H), 0.85 (dt, *J* = 10.7, 5.4 Hz, 6H), 0.77 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 165.30, 141.62, 134.50, 127.26, 126.04, 124.11, 120.64, 111.52, 111.28, 84.93, 76.73, 50.88, 46.52, 38.88, 37.67, 35.01, 28.23, 26.83, 25.66, 24.70, 23.60, 22.91, 21.79; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₅H₃₄N₄O₃B: 449.2724, found: 449.2725; Purity by HPLC: 98%.

[(1*R*)-1-[2-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)acetamido]-3-methylbutyl]boronic acid (33**)**




To a stirred solution of 2-(2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (**29**, 58 mg, 0.13 mmol, 1.0 equiv.) in acetone (6 mL) and H₂O (6 mL), NaIO₄ (83 mg, 0.39 mmol, 3.0 equiv.) and NH₄OAc (24 mg, 0.31 mmol, 2.4 equiv.) were added and the mixture was allowed to stir at room temperature for 16 h. The mixture was then diluted with H₂O (10 mL), pH was adjusted to 3 with 1 M HCl, and it was extracted with EtOAc (3 × 20 mL). The combined organic layers were removed under reduced pressure and the crude residue was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The obtained viscous oil was triturated with Et₂O (10 mL) and concentrated. The product [(1*R*)-1-[2-(2-cyano-1*H*-1,3-benzodiazol-1-yl)acetamido]-3-methylbutyl]boronic acid (**33**) was obtained as a white powder (20 mg, 49% yield). Mp.: 120–121 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.82 (d, *J* = 8.5 Hz, 1H), 7.83 (d, *J* = 8.2 Hz, 1H), 7.66 (d, *J* = 8.3 Hz, 1H), 7.51 (t, *J* = 7.7 Hz, 1H), 7.42 (t, *J* = 7.7 Hz, 1H), 5.14 – 5.11 (m, 2H), 1.67 (dp, *J* = 13.5, 6.8 Hz, 1H), 1.47 (dt, *J* = 13.7, 6.9 Hz, 1H), 1.38 (dt, *J* = 13.4, 6.7 Hz, 1H), 1.27 – 1.21 (m, 1H), 0.90 – 0.82 (m, 6H); ¹³C NMR (126 MHz, DMSO-*d*₆) 164.46, 141.61, 134.59, 127.37, 126.17, 124.17, 120.72, 111.44, 111.40, 71.56, 47.03, 45.12, 24.02, 22.49, 22.30; HRMS (ESI⁻) *m/z* [M-H]⁻, calcd. for C₁₅H₁₈N₄O₃B: 313.1472, found: 313.1478; Purity by HPLC: 97%.

3-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)propanoic acid (XXXI)




1*H*-1,3-Benzodiazole-2-carbonitrile (**XXIX**, 408 mg, 2.85 mmol, 1.0 equiv.) was dissolved in DMF (15 mL) and DIPEA (993 μL, 5.70 mmol, 2.0 equiv.). Ethyl 3-bromopropionate (534 μL, 4.28 mmol, 1.5 equiv.) was then added dropwise and the reaction mixture was stirred at 140 °C for 16 h. After the reaction was complete, it was diluted with THF (20 mL) and H₂O (30 mL). K₂CO₃ (788 mg, 5.70 mmol, 2.0 equiv.) was then added and the reaction mixture was allowed to stir at room temperature for 16 h. The mixture was concentrated, the residue re-dissolved in H₂O (80 mL), and washed with EtOAc (100 mL). The aqueous layer was acidified to pH 1 with 1 M HCl and extracted with EtOAc (3 × 80 mL). The combined organic layers were dried (MgSO₄), filtered, and the volatiles were removed under reduced pressure. The crude residue was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-(2-cyano-1*H*-1,3-benzodiazol-1-yl)propanoic acid (**XXXI**) was obtained as a yellow powder (150 mg, 24% yield). Mp.: 163–166 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 7.81 (dd, *J* = 13.1, 8.3 Hz, 2H), 7.50 (dd, *J* = 11.4, 4.0 Hz, 1H), 7.40 (t, *J* = 7.4 Hz, 1H), 4.64 (t, *J* = 6.6 Hz, 2H), 2.91 (t, *J* = 6.6 Hz, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 171.72, 141.98, 133.68, 126.97, 126.07, 124.15, 120.78, 112.01, 111.57, 41.33, 33.24; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₁₁H₁₀N₃O₂: 216.0773, found: 216.0768; Purity by HPLC: 99%.

3-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (30)



To a stirred solution of 3-(2-cyano-1*H*-1,3-benzodiazol-1-yl)propanoic acid (**XXXI**, 44 mg, 0.21 mmol, 1.0 equiv.), HATU (86 mg, 0.23 mmol, 1.1 equiv.) and DIPEA (79 μ L, 0.45 mmol, 2.2 equiv.) in DMF (2.5 mL), (*R*)-BoroLeu(+)-pinanediol trifluoroacetate (78 mg, 0.20 mmol, 1.0 equiv.) was added and the mixture was allowed to stir at room temperature for 2 h. The mixture was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The obtained viscous oil was triturated with Et₂O (20 mL) and concentrated. The product 3-(2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**30**) was obtained as a white powder (68 mg, 72% yield). Mp.: 52–55 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.71 (s, 1H), 7.78 (t, *J* = 9.0 Hz, 2H), 7.48 (dd, *J* = 11.3, 4.1 Hz, 1H), 7.43 – 7.36 (m, 1H), 4.66 (t, *J* = 6.4 Hz, 2H), 4.08 (dd, *J* = 8.5, 1.8 Hz, 1H), 2.87 (t, *J* = 6.4 Hz, 2H), 2.46 (t, *J* = 6.0 Hz, 1H), 2.24 – 2.14 (m, 1H), 2.04 – 1.96 (m, 1H), 1.83 (t, *J* = 5.5 Hz, 1H), 1.80 – 1.74 (m, 1H), 1.59 (d, *J* = 13.9 Hz, 1H), 1.43 – 1.32 (m, 1H), 1.27 – 1.20 (m, 7H), 1.12 – 1.02 (m, 2H), 0.80 (s, *J* = 12.2 Hz, 3H), 0.72 (d, *J* = 6.4 Hz, 6H); ¹³C NMR (126 MHz, DMSO-*d*₆) 171.26, 141.87, 133.76, 126.66, 125.95, 124.01, 120.60, 112.08, 111.46, 83.10, 75.74, 51.54, 41.43, 39.26, 37.61, 35.88, 32.24, 28.75, 27.06, 25.81, 24.66, 23.81, 22.99, 21.64; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₆H₃₆N₄O₃B: 463.2880, found: 463.2888; Purity by HPLC: 100%.


[(1*R*)-1-[3-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)propanamidol]-3-methylbutyl]boronic acid (34)



To a solution of 3-(2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**30**, 14 mg, 0.03 mmol, 1.0 equiv.) and 2-methyl-1-propylboronic acid (18 mg, 0.18 mmol, 6.0 equiv.) in MeOH (1.0 mL), 1 M HCl (100 μ L) and *n*-hexane (1.0 mL) were added, and the biphasic reaction mixture was allowed to stir vigorously at room temperature for 16 h. The *n*-hexane layer was discarded, the MeOH layer washed again with *n*-hexane (3 \times 1 mL), and finally concentrated. The residue was re-dissolved in diisopropyl ether (2.0


mL), sonicated for 15 min, followed by decanting and concentrating the ether. The residue was re-dissolved in MeCN (1.8 mL), sonicated for 15 min, decanted, and the MeCN solution was concentrated. The product [(1*R*)-1-[3-(2-cyano-1*H*-1,3-benzodiazol-1-yl)propanamido]-3-methylbutyl]boronic acid (**34**) was obtained as a yellow solid (5 mg, 51% yield). Mp.: 185–189 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.14 (s, 1H), 7.77 (t, *J* = 8.2 Hz, 2H), 7.41 (dt, *J* = 14.1, 7.6 Hz, 2H), 4.80 – 4.56 (m, 2H), 3.17 (s, 1H), 2.82 (ddd, *J* = 43.4, 10.9, 5.0 Hz, 2H), 1.26 (dd, *J* = 12.9, 6.2 Hz, 1H), 1.03 (ddd, *J* = 48.3, 26.5, 20.1 Hz, 2H), 0.84 – 0.56 (m, 6H); ¹³C NMR (126 MHz, DMSO-*d*₆) 163.00, 141.83, 133.82, 126.56, 126.03, 124.08, 120.60, 112.18, 111.44, 42.02, 41.51, 32.24, 24.94, 23.03, 22.23; HRMS (ESI⁻) *m/z* [M-H]⁻, calcd. for C₁₆H₂₀N₄O₃B: 327.1628, found: 327.1628; Purity by ¹H NMR: 97%.

4-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)butanoic acid (XXXII)




1*H*-1,3-Benzodiazole-2-carbonitrile (**XXIX**, 495 mg, 3.46 mmol, 1.0 equiv.) was dissolved in DMF (15 mL) and DIPEA (1205 μL, 6.92 mmol, 2.0 equiv.). Ethyl 4-bromobutyrate (834 μL, 6.23 mmol, 1.8 equiv.) was then added dropwise and the reaction mixture was stirred at 120 °C for 16 h. After the reaction was complete, it was diluted THF (20 mL) and H₂O (30 mL). K₂CO₃ (956 mg, 6.92 mmol, 2.0 equiv.) was then added and the reaction mixture was allowed to stir at room temperature for 16 h. The mixture was concentrated, the residue re-dissolved in H₂O (80 mL) and washed with EtOAc (100 mL). The aqueous layer was acidified to pH 1 with 1 M HCl and extracted with EtOAc (3 × 80 mL). The combined organic layers were dried (MgSO₄), filtered, and the volatiles were removed under reduced pressure. The crude residue was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 4-(2-cyano-1*H*-1,3-benzodiazol-1-yl)butanoic acid (**XXXII**) was obtained as a white powder (195 mg, 25% yield). Mp.: 132–134 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 12.18 (s, 1H), 7.81 (d, *J* = 7.8 Hz, 2H), 7.51 (dd, *J* = 10.5, 4.9 Hz, 1H), 7.41 (dd, *J* = 10.2, 5.1 Hz, 1H), 4.47 (dd, *J* = 9.3, 4.5 Hz, 2H), 2.36 – 2.28 (m, 2H), 2.13 – 2.02 (m, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 173.40, 141.95, 134.11, 126.15, 124.17, 120.83, 111.68, 111.45, 44.41, 30.42, 24.78; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₁₂H₁₂N₃O₂: 230.0930, found: 230.0928; Purity by HPLC: 98%.

4-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]butanamide (**31**)




To a stirred solution of 4-(2-cyano-1*H*-1,3-benzodiazol-1-yl)butanoic acid (**XXXII**, 92 mg, 0.40 mmol, 1.0 equiv.), HATU (167 mg, 0.44 mmol, 1.1 equiv.) and DIPEA (153 μ L, 0.88 mmol, 2.2 equiv.) in DMF (2.5 mL), (*R*)-BoroLeu(+)-pinanediol trifluoroacetate (152 mg, 0.40 mmol, 1.0 equiv.) was added and the mixture was allowed to stir at room temperature for 2 h. The mixture was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The obtained viscous oil was triturated with Et₂O (20 mL) and concentrated. The product 4-(2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]butanamide (**31**) was obtained as a white powder (156 mg, 82% yield). Mp.: 72–74 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 9.14 (s, 1H), 7.83 (d, *J* = 8.9 Hz, 2H), 7.51 (t, *J* = 8.1 Hz, 1H), 7.43 (t, *J* = 7.9 Hz, 1H), 4.47 (t, *J* = 7.2 Hz, 2H), 4.04 (dd, *J* = 8.5, 1.9 Hz, 1H), 2.45 (t, *J* = 7.1 Hz, 1H), 2.37 – 2.31 (m, 2H), 2.23 – 2.15 (m, 1H), 2.13 – 2.06 (m, 2H), 1.99 (dt, *J* = 6.3, 5.3 Hz, 1H), 1.82 (t, *J* = 5.6 Hz, 1H), 1.80 – 1.75 (m, 1H), 1.70 – 1.59 (m, 2H), 1.37 (d, *J* = 9.9 Hz, 1H), 1.27 – 1.19 (m, 8H), 0.82 (dt, *J* = 11.2, 5.5 Hz, 9H); ¹³C NMR (126 MHz, DMSO-*d*₆) 174.69, 141.93, 134.11, 126.13, 124.23, 120.85, 111.70, 111.47, 82.13, 75.36, 51.96, 44.28, 40.53, 37.62, 36.50, 29.19, 28.01, 27.19, 25.95, 25.17, 24.98, 23.94, 23.16, 21.85; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₇H₃₈N₄O₃B: 477.3037, found: 477.3030; Purity by HPLC: 99%.

[(1*R*)-1-[4-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)butanamido]-3-methylbutyl]boronic acid (**35**)




To a solution of 4-(2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]butanamide (**31**, 26 mg, 0.055 mmol, 1.0 equiv.) in diisopropyl ether (2.0 mL), boric acid (10 mg, 0.17 mmol, 3.0 equiv.) and concentrated HCl (120 μ L) were added, and the reaction mixture was allowed to stir vigorously at room temperature for 16 h. It was then diluted with diisopropyl ether (1.5 mL), sonicated, and the ether layer decanted. The residue was washed with diisopropyl ether (2 \times 2 mL), re-dissolved in MeCN (2.0 mL), sonicated for 15 min, decanted, and the MeCN solution was concentrated. The product [(1*R*)-1-[4-(2-cyano-1*H*-1,3-benzodiazol-1-yl)butanamido]-3-methylbutyl]boronic acid (**35**) was obtained as a white solid (8 mg, 43% yield). Mp.: 215–220 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 10.15 (s, *J* = 5.2 Hz, 1H), 7.83 (d, *J* = 8.5 Hz, 2H), 7.53 (t, *J* = 7.8 Hz, 1H), 7.48 – 7.38 (m, 1H), 4.66 (t, *J* = 6.8 Hz, 1H), 4.48 (t, *J* = 6.9 Hz, 2H), 2.48 – 2.44 (m, 1H), 2.36 (t, *J* = 7.5 Hz, 1H), 2.12 (dt, *J* = 11.7, 7.6 Hz, 2H), 1.54 (dt, *J* = 13.0, 6.5 Hz, 1H), 1.25 – 1.13 (m, 2H), 0.87 – 0.61 (m, 6H); ¹³C NMR (126 MHz, DMSO-*d*₆) 176.85, 142.01, 134.14, 126.40, 126.26, 124.38, 120.94, 111.83, 111.59, 46.64, 44.18, 26.47, 25.65, 24.97, 23.24, 21.96; HRMS (ESI⁻) *m/z* [M-H]⁻, calcd. for C₁₇H₂₂N₄O₃B: 341.1785, found: 341.1792; Purity by ¹H NMR: 97%.

5-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)pentanoic acid (**XXXIII**)



1*H*-1,3-Benzodiazole-2-carbonitrile (**XXIX**, 429 mg, 3.00 mmol, 1.0 equiv.) was dissolved in DMF (15 mL) and DIPEA (1045 μ L, 6.00 mmol, 2.0 equiv.). Ethyl 5-bromovalerate (855 μ L, 5.40 mmol, 1.8 equiv.) was then added dropwise and the reaction mixture was stirred reflux for 3 h. After the reaction was complete, it was diluted with THF (20 mL) and H₂O (60 mL). K₂CO₃ (1659 mg, 12.00 mmol, 4.0 equiv.) was then added and the reaction mixture was allowed to stir at room temperature for 16 h. The mixture was concentrated, the residue was re-dissolved in H₂O (80 mL) and washed with EtOAc (100 mL). The aqueous layer was acidified to pH 1 with 1 M HCl and extracted with EtOAc (3 \times 80 mL). The combined organic layers were dried (MgSO₄), filtered, and the volatiles were removed under reduced pressure. The crude residue was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 5-(2-cyano-1*H*-1,3-benzodiazol-1-yl)pentanoic acid (**XXXIII**) was obtained as a white powder (206 mg, 28% yield). Mp.: 104–105 $^{\circ}$ C; ¹H NMR (500 MHz, DMSO-*d*₆) 12.02 (s, 1H), 7.81 (d, *J* = 8.5 Hz, 2H), 7.51 (t, *J* = 7.7 Hz, 1H), 7.41 (t, *J* = 7.8 Hz, 1H), 4.47 (t, *J* = 7.0 Hz, 2H), 2.29 – 2.22 (m, 2H), 1.91 – 1.82 (m, 2H), 1.49 (dt, *J* = 10.5, 7.5 Hz, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 173.98, 141.93, 134.12, 126.15, 126.10, 124.18, 120.82, 111.80, 111.56, 44.87, 32.92, 28.87, 21.59; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₁₃H₁₄N₃O₂: 244.1086, found: 244.1083; Purity by HPLC: 98%.


5-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]pentanamide (32)



To a stirred solution of 5-(2-cyano-1*H*-1,3-benzodiazol-1-yl)pentanoic acid (**XXXIII**, 110 mg, 0.45 mmol, 1.0 equiv.), HATU (188 mg, 0.50 mmol, 1.1 equiv.) and DIPEA (172 μ L, 0.99 mmol, 2.2 equiv.) in DMF (2.5 mL), (*R*)-BoroLeu-(+)-pinediol trifluoroacetate (171 mg, 0.45 mmol, 1.0 equiv.) was added and the mixture was allowed to stir at room temperature for 2 h. The mixture was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The obtained viscous oil was triturated with Et₂O (20 mL) and concentrated. The product 5-(2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(*S**R*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]pentanamide (**32**) was obtained as a light brown powder (183 mg, 83% yield). Mp.: 147–149 $^{\circ}$ C; ¹H NMR (500 MHz, DMSO-*d*₆) 9.24 (s, 1H), 7.82 (dd, *J* = 8.3, 2.5 Hz, 2H), 7.50 (t, *J* = 7.8 Hz, 1H), 7.42 (t, *J* = 7.6 Hz, 1H), 4.47 (t, *J* = 7.1 Hz, 2H), 3.94 (dd, *J* = 8.5, 1.9 Hz, 1H), 2.42 – 2.36 (m, 1H), 2.31 (t, *J* = 7.3 Hz, 2H), 2.19 – 2.11


(m, 1H), 1.98 – 1.90 (m, 1H), 1.89 – 1.81 (m, 2H), 1.80 – 1.72 (m, 2H), 1.65 (td, $J = 13.4, 6.7$ Hz, 1H), 1.60 – 1.51 (m, 3H), 1.34 (t, $J = 8.3$ Hz, 1H), 1.23 – 1.16 (m, 8H), 0.83 (dd, $J = 6.6, 3.0$ Hz, 6H), 0.79 (s, 3H); ^{13}C NMR (126 MHz, DMSO- d_6) 175.71, 141.92, 134.07, 126.08, 126.04, 124.15, 120.78, 111.80, 111.49, 81.73, 75.16, 52.04, 44.76, 40.70, 37.57, 36.61, 30.14, 29.20, 28.79, 27.22, 25.92, 24.98, 23.94, 23.11, 22.06, 21.95; HRMS (ESI⁺) m/z [M+H]⁺, calcd. for C₂₈H₄₀N₄O₃B: 491.3193, found: 491.3194; Purity by HPLC: 98%.

[(1R)-1-[5-(2-Cyano-1H-1,3-benzodiazol-1-yl)pentanamido]-3-methylbutyl]boronic acid (36)



To a solution of 5-(2-cyano-1H-1,3-benzodiazol-1-yl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]pentanamide (**32**, 39 mg, 0.08 mmol, 1.0 equiv.) and 2-methyl-1-propylboronic acid (25 mg, 0.24 mmol, 3.0 equiv.) in MeOH (1.0 mL), 1 M HCl (240 μL) and *n*-hexane (1.0 mL) were added, and the biphasic reaction mixture was allowed to stir vigorously at room temperature for 16 h. The *n*-hexane layer was discarded, the MeOH layer washed again with *n*-hexane (3 \times 1 mL), and finally concentrated. The residue was re-dissolved in diisopropyl ether (2.0 mL), sonicated for 15 min, followed by decanting and concentrating the ether. The residue was re-dissolved in MeCN (1.8 mL), sonicated for 15 min, decanted, and the MeCN solution was concentrated. The product [(1R)-1-[5-(2-cyano-1H-1,3-benzodiazol-1-yl)pentanamido]-3-methylbutyl]boronic acid (**36**) was obtained as a white solid (18 mg, 63%). Mp.: 95–98 $^{\circ}\text{C}$; ^1H NMR (500 MHz, DMSO- d_6) 7.82 (dt, $J = 12.6, 8.1$ Hz, 2H), 7.51 (dt, $J = 15.4, 7.7$ Hz, 1H), 7.41 (ddd, $J = 14.0, 7.9, 5.1$ Hz, 1H), 4.46 (dt, $J = 17.8, 7.1$ Hz, 2H), 2.56 – 2.51 (m, 1H), 2.43 (s, 1H), 2.35 (d, $J = 15.3$ Hz, 1H), 1.92 – 1.79 (m, 2H), 1.53 (ddd, $J = 15.6, 12.5, 7.5$ Hz, 3H), 1.27 – 1.11 (m, 2H), 0.85 – 0.79 (m, 3H), 0.76 (dd, $J = 6.5, 3.9$ Hz, 3H); ^{13}C NMR (126 MHz, DMSO- d_6) 141.94, 134.11, 134.05, 126.18, 126.13, 124.18, 120.81, 111.81, 111.52, 44.73, 28.74, 25.24, 25.02, 23.17, 22.97, 22.29, 21.86; HRMS (ESI⁻) m/z [M-H]⁻, calcd. for C₁₈H₂₄N₄O₃B: 355.1941, found: 355.1936; Purity by ^1H NMR: 99%.


3-[(5-Chloro-2-nitrophenyl)amino]propanoic acid (XXXVI)



To a stirred solution of 4-chloro-2-fluoronitrobenzene (**XXXIV**, 488 mg, 2.78 mmol, 1.0 equiv.) in DMF (4.0 mL) and DIPEA (1453 μL , 8.34 mmol, 3.0 equiv.), ethyl 3-aminopropanoate hydrochloride (512 mg, 3.34 mmol, 1.2 equiv.) was added and the mixture was allowed to stir at room temperature for 16 h. The mixture was diluted with DMF (4 mL), THF (10 mL) and H₂O (20 mL), followed by the addition


of 10% NaOH (8.0 mL). The reaction mixture was stirred at 70 °C for 2 h. After the reaction was complete, THF was evaporated, the remaining suspension diluted with H₂O (60 mL), the pH adjusted to 1 with 10% HCl, and finally extracted with EtOAc (3 × 60 mL). The combined organic layers were dried (MgSO₄), volatiles evaporated and the product was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-[(5-chloro-2-nitrophenyl)amino]propanoic acid (**XXXVI**) was obtained as a yellow solid (597 mg, 88% yield). Mp.: 150–152 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 12.40 (s, 1H), 8.28 (t, *J* = 5.5 Hz, 1H), 8.06 (d, *J* = 9.1 Hz, 1H), 7.16 (d, *J* = 1.5 Hz, 1H), 6.70 (dd, *J* = 9.1, 1.9 Hz, 1H), 3.58 (q, *J* = 6.3 Hz, 2H), 2.61 (t, *J* = 6.6 Hz, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 172.89, 145.36, 141.70, 130.08, 128.23, 115.42, 113.44, 38.38, 33.16; HRMS (ESI⁻) *m/z* [M-H]⁻, calcd. for C₉H₈N₂O₄Cl: 243.0173, found: 243.0174; Purity by HPLC: 99%.

3-[(5-Chloro-2-nitrophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (XXXVIII**)**




To a stirred solution of 3-[(5-chloro-2-nitrophenyl)amino]propanoic acid (**XXXVI**, 196 mg, 0.80 mmol, 1.0 equiv.), HATU (335 mg, 0.88 mmol, 1.1 equiv.) and DIPEA (307 μL, 1.76 mmol, 2.2 equiv.) in DMF (2.5 mL), (*R*)-BoroLeu(+)-pinanediol trifluoroacetate (303 mg, 0.80 mmol, 1.0 equiv.) was added and the mixture was allowed to stir at room temperature for 2 h. The mixture was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-[(5-chloro-2-nitrophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**XXXVIII**) was obtained as a yellow solid (362 mg, 92% yield). Mp.: 58–60 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 9.11 (s, 1H), 8.27 (t, *J* = 5.8 Hz, 1H), 8.08 (d, *J* = 9.1 Hz, 1H), 7.16 (d, *J* = 2.0 Hz, 1H), 6.72 (dd, *J* = 9.1, 2.0 Hz, 1H), 4.06 – 4.00 (m, 1H), 3.61 (q, *J* = 6.4 Hz, 2H), 2.64 – 2.57 (m, 2H), 2.21 – 2.13 (m, 1H), 2.02 – 1.93 (m, 1H), 1.80 (t, *J* = 5.6 Hz, 1H), 1.78 – 1.74 (m, 1H), 1.62 (td, *J* = 14.2, 9.4 Hz, 2H), 1.33 (d, *J* = 10.0 Hz, 1H), 1.30 – 1.16 (m, 9H), 0.83 (dd, *J* = 6.6, 2.1 Hz, 6H), 0.79 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 173.37, 145.24, 141.62, 130.13, 128.17, 115.48, 113.50, 82.45, 75.49, 51.80, 40.44, 38.70, 37.60, 36.24, 31.06, 28.95, 27.13, 25.89, 24.92, 23.88, 23.09, 21.86; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₄H₃₆N₃O₅BCl: 492.2437, found: 492.2437; Purity by HPLC: 99%.

3-[(2-Amino-5-chlorophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (XL**)**



To a solution of 3-[(2-amino-5-chlorophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**XL**, 246 mg, 0.50 mmol, 1.0 equiv.) in EtOAc (25 mL), SnCl₂ × 2H₂O (677 mg, 3.00 mmol, 6.0 equiv.) was added and the reaction was allowed to proceed at 70 °C for 2 h. Then, another portion of SnCl₂ × 2H₂O (451 mg, 2.00 mmol, 4.0 equiv.) was added and the reaction was allowed to stir at 70 °C for additional 16 h. The formerly yellow reaction mixture became colourless. It was then diluted with EtOAc (100 mL) and washed with saturated aqueous solution of NaHCO₃ (2 × 100 mL) and brine (50 mL). The volatiles were evaporated and the mixture was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-[(2-amino-5-chlorophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**XL**) was obtained as a white solid (193 mg, 84% yield). Mp.: 59–61 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 9.29 (s, 1H), 6.53 (d, *J* = 8.0 Hz, 1H), 6.43 (dt, *J* = 4.9, 2.2 Hz, 2H), 4.77 (s, 2H), 4.02 (dd, *J* = 8.5, 1.9 Hz, 1H), 3.27 (t, *J* = 6.9 Hz, 2H), 2.56 (t, *J* = 7.0 Hz, 2H), 2.45 (t, *J* = 7.3 Hz, 1H), 2.22 – 2.14 (m, 1H), 2.08 – 2.05 (m, 2H), 2.02 – 1.95 (m, 1H), 1.82 (t, *J* = 5.6 Hz, 1H), 1.80 – 1.75 (m, 1H), 1.69 (dq, *J* = 13.0, 6.6 Hz, 1H), 1.63 (d, *J* = 13.8 Hz, 1H), 1.39 (d, *J* = 9.9 Hz, 1H), 1.27 – 1.21 (m, 8H), 0.86 (dd, *J* = 6.4, 4.8 Hz, 6H), 0.81 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 74.59, 136.69, 134.46, 121.08, 116.28, 114.65, 109.44, 81.91, 75.25, 52.05, 40.67, 39.27, 37.61, 36.59, 31.08, 29.26, 27.22, 25.98, 25.02, 23.96, 23.14, 22.00; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₄H₃₈N₃O₃BCl: 462.2695, found: 462.2691; Purity by HPLC: 98%.

3-(6-Chloro-2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (37)




To a solution of 3-[(2-amino-5-chlorophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**XL**, 46 mg, 0.10 mmol, 1.0 equiv.) in pyridine (800 μL), Appel's salt (21 mg, 0.10 mmol, 1.0 equiv.) was added. The reaction mixture was allowed to stir first at room temperature for 1 h and then at 50 °C for 3 h. After the reaction was

complete, the product was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-(6-chloro-2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**37**) was obtained as a brown solid (21 mg, 42% yield).


Mp.: 172–175 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.68 (s, 1H), 7.94 (d, *J* = 1.8 Hz, 1H), 7.80 (d, *J* = 8.8 Hz, 1H), 7.41 (dd, *J* = 8.8, 1.9 Hz, 1H), 4.64 (t, *J* = 6.4 Hz, 2H), 4.06 (d, *J* = 6.8 Hz, 1H), 2.87 (t, *J* = 6.3 Hz, 2H), 2.49 – 2.46 (m, 1H), 2.21 – 2.13 (m, 1H), 2.02 – 1.95 (m, 1H), 1.82 (t, *J* = 5.6 Hz, 1H), 1.77 (s, 1H), 1.57 (d, *J* = 14.1 Hz, 1H), 1.34 (dd, *J* = 13.6, 6.6 Hz, 1H), 1.23 – 1.19 (m, 7H), 1.07 (dt, *J* = 14.8, 7.2 Hz, 2H), 0.79 (s, 3H), 0.72 (d, *J* = 6.6 Hz, 6H); ¹³C NMR (126 MHz, DMSO-*d*₆) 171.10, 140.52, 134.47, 130.81, 127.75, 124.69, 121.99, 112.17, 111.15, 83.19, 75.78, 51.50, 41.65, 39.90, 37.62, 35.83, 32.18, 28.70, 27.06, 25.80, 24.68, 23.81, 22.98, 21.67; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₆H₃₅N₄O₃BCl: 497.2491, found: 497.2497; Purity by HPLC: 99%.

3-[(2-Chloro-6-nitrophenyl)amino]propanoic acid (XXXVII)




To a stirred solution of 1-chloro-2-fluoro-3-nitrobenzene (**XXXV**, 560 mg, 3.19 mmol, 1.0 equiv.) in DMF (4.0 mL) and DIPEA (1667 μL, 9.57 mmol, 3.0 equiv.), ethyl 3-aminopropanoate hydrochloride (588 mg, 3.83 mmol, 1.2 equiv.) was added and the mixture was allowed to stir at room temperature for 16 h. The mixture was diluted with DMF (4 mL), THF (10 mL), and H₂O (20 mL), followed by the addition of 10% NaOH (8.0 mL). The reaction mixture was allowed to proceed at 70 °C for 2 h. After the reaction was complete, THF was evaporated, the remaining suspension diluted with H₂O (60 mL), pH adjusted to 1 with 10% HCl, and then extracted with EtOAc (3 × 60 mL). The combined organic layers were dried (MgSO₄), volatiles evaporated and the product was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-[(2-chloro-6-nitrophenyl)amino]propanoic acid (**XXXVII**) was obtained as a yellow solid (580 mg, 74% yield). Mp.: 65–68 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 12.36 (s, 1H), 7.85 (dd, *J* = 8.4, 1.4 Hz, 1H), 7.67 (dd, *J* = 7.8, 1.4 Hz, 1H), 6.88 (t, *J* = 8.1 Hz, 1H), 6.51 (t, *J* = 5.9 Hz, 1H), 3.37 (q, *J* = 6.3 Hz, 2H), 2.54 (t, *J* = 6.4 Hz, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 172.87, 140.99, 138.82, 135.46, 125.15, 123.92, 118.26, 42.54, 34.49; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₉H₁₀N₂O₄Cl: 245.0329, found: 245.0324; Purity by HPLC: 99%.

3-[(2-Chloro-6-nitrophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (XXXIX)



To a stirred solution of 3-[(2-chloro-6-nitrophenyl)amino]propanoic acid (**XXXVII**, 269 mg, 1.10 mmol, 1.0 equiv.), HATU (460 mg, 1.21 mmol, 1.1 equiv.) and DIPEA (422 μ L, 2.42 mmol, 2.2 equiv.) in DMF (2.5 mL), (*R*)-BoroLeu(+)-pinanediol trifluoroacetate (417 mg, 1.10 mmol, 1.0 equiv.) was added and the mixture was allowed to stir at room temperature for 2 h. The mixture was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-[(2-chloro-6-nitrophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**XXXIX**) was obtained as a yellow solid (457 mg, 84% yield). Mp.: 145–146 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 9.08 (s, 1H), 7.85 (d, *J* = 8.4 Hz, 1H), 7.67 (d, *J* = 7.8 Hz, 1H), 6.88 (t, *J* = 8.1 Hz, 1H), 6.51 (t, *J* = 5.7 Hz, 1H), 4.00 (d, *J* = 7.4 Hz, 1H), 3.38 (q, *J* = 6.2 Hz, 2H), 2.56 (t, *J* = 6.4 Hz, 2H), 2.46 (d, *J* = 6.9 Hz, 1H), 2.21 – 2.12 (m, 1H), 2.00 – 1.93 (m, 1H), 1.80 (t, *J* = 5.5 Hz, 1H), 1.76 (d, *J* = 5.2 Hz, 1H), 1.64 (ddd, *J* = 23.7, 14.8, 10.2 Hz, 2H), 1.32 (d, *J* = 10.0 Hz, 1H), 1.26 – 1.16 (m, 8H), 0.84 (t, *J* = 6.5 Hz, 6H), 0.79 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 173.48, 140.69, 138.50, 135.33, 125.17, 123.75, 118.15, 82.35, 75.45, 51.81, 42.79, 40.41, 37.59, 36.27, 32.31, 28.96, 27.14, 25.89, 24.92, 23.89, 23.11, 21.88; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₄H₃₆N₃O₅BCl: 492.2437, found: 492.2440; Purity by HPLC: 99%.


3-[(2-Amino-6-chlorophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (XLI**)**



To a solution of 3-[(2-chloro-6-nitrophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**XXXIX**, 271 mg, 0.55 mmol, 1.0 equiv.) in EtOAc (25 mL), SnCl₂ × 2H₂O (745 mg, 3.30 mmol, 6.0 equiv.) was added and the reaction was allowed to proceed at 70 °C for 2 h. Then, another portion of SnCl₂ × 2H₂O (496 mg, 2.20 mmol, 4.0 equiv.) was added and the reaction was allowed to stir at 70 °C for additional 16 h. The formerly yellow reaction mixture became colourless. It was then diluted with EtOAc (100 mL), washed with saturated aqueous solution of NaHCO₃ (2 × 100 mL) and brine (50 mL). The volatiles were evaporated and the mixture was purified by reversed-phase flash column chromatography using eluents A (0.1%


HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-[(2-amino-6-chlorophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**XLI**) was obtained as a white solid (224 mg, 88% yield). Mp.: 57–59 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 9.29 (s, 1H), 6.73 (t, *J* = 7.9 Hz, 1H), 6.61 (dd, *J* = 8.0, 1.2 Hz, 1H), 6.56 (dd, *J* = 7.9, 1.2 Hz, 1H), 5.13 (s, 1H), 4.02 (dd, *J* = 8.5, 1.8 Hz, 1H), 3.11 – 3.03 (m, 2H), 2.58 – 2.51 (m, 2H), 2.47 – 2.42 (m, 1H), 2.22 – 2.15 (m, 1H), 1.99 (dd, *J* = 13.2, 7.1 Hz, 1H), 1.81 (ddd, *J* = 18.6, 8.2, 3.9 Hz, 2H), 1.73 – 1.66 (m, 1H), 1.62 (d, *J* = 13.7 Hz, 1H), 1.40 – 1.35 (m, 1H), 1.30 – 1.20 (m, 9H), 0.86 (t, *J* = 6.0 Hz, 6H), 0.82 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 175.15, 144.25, 129.94, 127.81, 124.12, 116.26, 113.35, 81.84, 75.22, 52.05, 41.51, 40.71, 37.60, 36.64, 31.78, 29.28, 27.23, 26.00, 25.03, 23.97, 23.19, 21.90; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₄H₃₈N₃O₃BCl: 462.2695, found: 462.2685; Purity by HPLC: 98%.

3-(7-Chloro-2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (38)




To a solution of 3-[(2-amino-6-chlorophenyl)amino]-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**XLI**, 97 mg, 0.21 mmol, 1.0 equiv.) in pyridine (1500 μL), Appel's salt (44 mg, 0.21 mmol, 1.0 equiv.) was added. The reaction mixture was allowed to stir first at room temperature for 1 h and then at 70 °C for 6 h. After the reaction was complete, the product was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 3-(7-chloro-2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (**38**) was obtained as a light brown solid (35 mg, 34% yield). Mp.: 68–72 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 8.74 (d, *J* = 14.2 Hz, 1H), 7.79 (t, *J* = 6.3 Hz, 1H), 7.57 (t, *J* = 6.2 Hz, 1H), 7.40 (dd, *J* = 14.0, 5.9 Hz, 1H), 4.90 – 4.77 (m, 2H), 4.07 (t, *J* = 10.3 Hz, 1H), 2.92 (t, *J* = 6.7 Hz, 2H), 2.58 – 2.52 (m, 1H), 2.23 – 2.14 (m, 1H), 1.99 (dd, *J* = 9.4, 5.3 Hz, 1H), 1.82 (t, *J* = 5.6 Hz, 1H), 1.78 (d, *J* = 5.5 Hz, 1H), 1.58 (d, *J* = 13.9 Hz, 1H), 1.45 (dq, *J* = 13.2, 6.7 Hz, 1H), 1.26 – 1.19 (m, 9H), 0.78 (dd, *J* = 11.2, 5.2 Hz, 9H). ¹³C NMR (126 MHz, DMSO-*d*₆) 170.68, 144.11, 129.67, 129.11, 127.26, 124.96, 120.24, 116.09, 110.90, 83.24, 75.81, 51.50, 43.04, 39.94, 37.64, 35.83, 33.98, 28.68, 27.07, 25.82, 24.75, 23.83, 23.04, 21.74; HRMS (ESI⁻) *m/z* [M-H]⁻, calcd. for C₂₆H₃₃N₄O₃BCl: 495.2334, found: 495.2314; Purity by HPLC: 98%.

2-(3-Amino-4-hydroxyphenyl)acetic acid hydrochloride (XLIII)




Methyl 2-(3-amino-4-hydroxyphenyl)acetate (**XLII**, 399 mg, 2.20 mmol) was suspended in 20% HCl (25 mL) and the mixture was allowed to reflux for 3 h. The volatiles were evaporated and the residue was triturated with Et₂O (30 mL). After filtration, the solid was washed with Et₂O (2 × 30 mL). The product 2-(3-amino-4-hydroxyphenyl)acetic acid hydrochloride (**XLIII**) was obtained as a brown solid (438 mg, 98% yield). Mp.: 186–189 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 10.65 (s, 1H), 9.92 (s, 1H), 7.23 (d, *J* = 2.0 Hz, 1H), 7.08 (dd, *J* = 8.3, 1.9 Hz, 1H), 7.00 (d, *J* = 8.3 Hz, 1H), 3.48 (s, 2H); ¹³C NMR (126 MHz, DMSO-*d*₆) 172.64, 149.41, 129.80, 125.96, 124.59, 119.07, 115.99, 39.58; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₈H₁₀NO₃: 168.0661, found: 168.0659; Purity by HPLC: 100%.

2-(3-Amino-4-hydroxyphenyl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (XLIV**)**




To a stirred solution of 2-(3-amino-4-hydroxyphenyl)acetic acid hydrochloride (**XLIII**, 244 mg, 1.2 mmol, 1.0 equiv.), HATU (546 mg, 1.44 mmol, 1.2 equiv.) and DIPEA (669 μL, 3.84 mmol, 3.2 equiv.) in DMF (4.0 mL), (*R*)-BoroLeu-(+)-pinediol trifluoroacetate (548 mg, 1.44 mmol, 1.2 equiv.) was added and the mixture was allowed to stir at room temperature for 2 h. The mixture was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 2-(3-amino-4-hydroxyphenyl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (**XLIV**) was obtained as a white powder (225 mg, 51% yield). Mp.: 91–93 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 9.36 (s, 1H), 6.56 (d, *J* = 7.9 Hz, 1H), 6.47 (d, *J* = 2.0 Hz, 1H), 6.28 (dd, *J* = 8.0, 2.0 Hz, 1H), 3.95 (dd, *J* = 8.4, 2.0 Hz, 1H), 3.39 – 3.30 (m, 2H), 2.39 (t, *J* = 7.5 Hz, 1H), 2.16 (dt, *J* = 11.0, 10.5 Hz, 1H), 2.00 – 1.91 (m, 1H), 1.81 – 1.65 (m, 3H), 1.59 (d, *J* = 13.8 Hz, 1H), 1.35 (t, *J* = 9.9 Hz, 1H), 1.26 – 1.18 (m, 9H), 0.85 (t, *J* = 6.1 Hz, 6H), 0.80 (s, 3H); ¹³C NMR (126 MHz, DMSO-*d*₆) 175.20, 143.00, 136.48, 124.78, 116.69, 114.92, 114.19, 81.61, 75.10, 52.15, 40.82, 37.58, 36.89, 36.71, 29.34, 27.25, 25.98, 25.06, 23.99, 23.14, 22.07; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₃H₃₆N₂O₄B: 415.2768, found: 415.2766; Purity by HPLC: 99%.

2-(2-Cyano-1,3-benzoxazol-5-yl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (39**)**



To a solution of 2-(3-amino-4-hydroxyphenyl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (**XLIV**, 166 mg, 0.40 mmol, 1.0 equiv.) in pyridine (3000 μ L), Appel's salt (100 mg, 0.48 mmol, 1.2 equiv.) was added. The reaction mixture was allowed to stir first at room temperature for 1 h and at 90 °C for 1 h. The product was purified by reversed-phase flash column chromatography using eluents A (0.1% HCOOH in MeCN) and B (0.1% HCOOH in H₂O) (gradient from 1:9 to 10:0). The product 2-(2-cyano-1,3-benzoxazol-5-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (**39**) was obtained as a brown solid (42 mg, 23% yield). Mp.: 60–65 °C; ¹H NMR (500 MHz, DMSO-*d*₆) 9.20 (d, *J* = 12.9 Hz, 1H), 7.91 – 7.85 (m, 2H), 7.58 (dd, *J* = 8.6, 1.3 Hz, 1H), 4.02 (d, *J* = 6.9 Hz, 1H), 3.76 (s, 2H), 2.57 – 2.52 (m, 1H), 2.21 – 2.14 (m, 1H), 2.00 – 1.94 (m, 1H), 1.81 (t, *J* = 5.6 Hz, 1H), 1.77 (d, *J* = 5.4 Hz, 1H), 1.69 (dq, *J* = 13.5, 6.8 Hz, 1H), 1.59 (d, *J* = 13.9 Hz, 1H), 1.30 (d, *J* = 7.6 Hz, 2H), 1.20 (d, *J* = 1.4 Hz, 6H), 0.85 (dd, *J* = 6.4, 4.7 Hz, 6H), 0.80 (d, *J* = 2.5 Hz, 1H), 0.79 (s, 3H). ¹³C NMR (126 MHz, DMSO-*d*₆) 172.93, 148.95, 138.95, 137.50, 133.89, 130.35, 121.39, 111.65, 109.70, 82.61, 75.58, 51.76, 40.42, 37.91, 37.64, 36.21, 28.99, 27.14, 25.89, 25.00, 23.89, 13.09, 22.00; HRMS (ESI⁺) *m/z* [M+H]⁺, calcd. for C₂₅H₃₃N₃O₄B: 450.2564, found: 450.2566; Purity by HPLC: 99%.

[(1*R*)-1-[2-(2-Cyano-1,3-benzoxazol-5-yl)acetamido]-3-methylbutyl]boronic acid (**40**)






To a solution of 2-(2-cyano-1,3-benzoxazol-5-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (**39**, 14 mg, 0.031 mmol, 1.0 equiv.) and 2-methyl-1-propylboronic acid (19 mg, 0.19 mmol, 6.0 equiv.) in MeOH (1.2 mL), 1 M HCl (100 μ L) and *n*-hexane (1.2 mL) were added, and the biphasic reaction mixture was allowed to stir vigorously at room temperature for 16 h. The *n*-hexane layer was discarded, the MeOH washed again with *n*-hexane (3 \times 1 mL), and finally concentrated. The residue was re-dissolved in diisopropyl ether (2.0 mL), sonicated for 15 min, followed by discarding the ether solution. The residue was re-dissolved in MeCN (2.0 mL), sonicated for 15 min, decanted, and the MeCN solution was concentrated. The product [(1*R*)-1-[2-(2-cyano-1,3-benzoxazol-5-yl)acetamido]-3-methylbutyl]boronic acid (**40**) was obtained as a yellow solid (8 mg, 80% yield). Mp.: 125–127 °C; ¹H NMR (300 MHz, DMSO-*d*₆) 8.13 (s, 1H), 7.85 (t, *J* = 7.8 Hz, 2H), 7.57 (d, *J* = 8.6 Hz, 1H), 3.78 (s, 2H), 1.53 (dd, *J* = 13.2, 6.5 Hz, 1H), 1.19 (dd, *J* = 13.8, 7.1 Hz, 3H), 0.89 – 0.73 (m, 7H). ¹³C NMR (75 MHz, DMSO-*d*₆) 163.00, 148.96, 138.94, 137.42,


133.69, 130.53, 121.62, 111.62, 109.68, 37.71, 25.11, 23.21, 23.01, 22.35; HRMS (ESI-) m/z $[M-H]^-$, calcd. for $C_{15}H_{17}N_3O_4B$: 314.1312, found: 314.1310; Purity by 1H NMR: 97%.

3. LC-MS chromatograms, 1H NMR and ^{13}C NMR spectra of the synthesized compounds



5-Methoxy-1,3-benzoxazole-2-thiol (VIII)













5-Nitro-1,3-benzoxazole-2-thiol (IX)









6-Methyl-1,3-benzoxazole-2-carbonitrile (5)









4-Methoxy-1,3-benzoxazole-2-carbonitrile (6)









5-Methoxy-1,3-benzoxazole-2-carbonitrile (7)








6-Methoxy-1,3-benzoxazole-2-carbonitrile (8)








7-Methoxy-1,3-benzoxazole-2-carbonitrile (9)









4-Hydroxy-1,3-benzoxazole-2-carbonitrile (10)










5-Hydroxy-1,3-benzoxazole-2-carbonitrile (11)









6-Hydroxy-1,3-benzoxazole-2-carbonitrile (12)








7-Hydroxy-1,3-benzoxazole-2-carbonitrile (13)









2-Cyano-1,3-benzoxazol-4-yl acetate (14)








2-Cyano-1,3-benzoxazol-5-yl acetate (15)









4-Nitro-1,3-benzoxazole-2-carbonitrile (16)








5-Nitro-1,3-benzoxazole-2-carbonitrile (17)









6-Nitro-1,3-benzoxazole-2-carbonitrile (18)









7-Nitro-1,3-benzoxazole-2-carbonitrile (19)









4-Amino-1,3-benzoxazole-2-carbonitrile (20)









5-Amino-1,3-benzoxazole-2-carbonitrile (21)









6-Amino-1,3-benzoxazole-2-carbonitrile (22)








7-Amino-1,3-benzoxazole-2-carbonitrile (23)








N-(2-cyano-1,3-benzoxazol-4-yl)benzamide (24)













N-(2-cyano-1,3-benzoxazol-5-yl)benzamide (25)








N-(2-cyano-1,3-benzoxazol-6-yl)benzamide (26)







N-(2-cyano-1,3-benzoxazol-7-yl)benzamide (27)













Methyl 2-(2-bromo-1,3-thiazol-4-yl)acetate (XXIV)








Methyl 2-(2-ethenyl-1,3-thiazol-4-yl)acetate (XXV)







2-(2-Ethenyl-1,3-thiazol-4-yl)acetic acid (XXVI)









2-(2-Ethenyl-1,3-thiazol-4-yl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (28)









2-(2-Cyano-1H-1,3-benzodiazol-1-yl)acetic acid (XXX)









2-(2-Cyano-1H-1,3-benzodiazol-1-yl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (29)









[(1R)-1-[2-(2-Cyano-1H-1,3-benzodiazol-1-yl)acetamido]-3-methylbutyl]boronic acid (33)









3-(2-Cyano-1H-1,3-benzodiazol-1-yl)propanoic acid (XXXI)








3-(2-Cyano-1H-1,3-benzodiazol-1-yl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (30)









[(1R)-1-[3-(2-Cyano-1H-1,3-benzodiazol-1-yl)propanamido]-3-methylbutyl]boronic acid (34)









4-(2-Cyano-1H-1,3-benzodiazol-1-yl)butanoic acid (XXXII)








4-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]butanamide (31)









[(1R)-1-[4-(2-Cyano-1H-1,3-benzodiazol-1-yl)butanamido]-3-methylbutyl]boronic acid (35)









5-(2-Cyano-1H-1,3-benzodiazol-1-yl)pentanoic acid (XXXIII)








5-(2-Cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]pentanamide (32)









[(1R)-1-[5-(2-Cyano-1H-1,3-benzodiazol-1-yl)pentanamido]-3-methylbutyl]boronic acid (36)









3-[(5-Chloro-2-nitrophenyl)amino]propanoic acid (XXXVI)









3-[(5-Chloro-2-nitrophenyl)amino]-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (XXXVIII)







3-[(2-Amino-5-chlorophenyl)amino]-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (XL)









3-(6-Chloro-2-cyano-1H-1,3-benzodiazol-1-yl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (37)






3-[(2-Chloro-6-nitrophenyl)amino]propanoic acid (XXXVII)







3-[(2-Chloro-6-nitrophenyl)amino]-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (XXXIX)











3-[(2-Amino-6-chlorophenyl)amino]-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (XLI)












3-(7-Chloro-2-cyano-1*H*-1,3-benzodiazol-1-yl)-*N*-[(1*R*)-3-methyl-1-[(1*S*,2*S*,6*R*,8*S*)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]propanamide (38)













2-(3-Amino-4-hydroxyphenyl)acetic acid hydrochloride (XLIII)









2-(3-Amino-4-hydroxyphenyl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxabicyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (XLIV)








2-(2-Cyano-1,3-benzoxazol-5-yl)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxo-4-boratricyclo[6.1.1.0^{2,6}]decan-4-yl]butyl]acetamide (39)





[(1R)-1-[2-(2-Cyano-1,3-benzoxazol-5-yl)acetamido]-3-methylbutyl]boronic acid (40)





4. Supplementary Tables and Figures

Table S1. Reactivity of benzoxazole-2-carbonitrile derivatives. Compounds were marked as hyperreactive when the reaction with *N*-acetyl cysteine was too fast to be monitored. Chemical shift of the CN peak in ^{13}C NMR, and the energy barrier of the reaction between the fragment and cysteamine are represented in the last two columns.






Substituent	Position	Label	Reactivity with <i>N</i> -acetyl cysteine (UV-Vis-based assay)	Reactivity with GSH (HPLC-based assay)	^{13}C NMR chemical shift of the CN peak in $\text{DMSO-}d_6$ [ppm]	Calculated barrier [kcal/mol]
-Me	6	5	low absorbance	$t_{1/2} < 3$ min	109.78	
-OMe	4	6	hyperreactive	$t_{1/2} < 3$ min	109.68	6.8
	5	7	hyperreactive	$t_{1/2} < 3$ min	109.67	7.4
	6	8	hyperreactive		109.85	8.1
	7	9	hyperreactive	$t_{1/2} < 3$ min	109.52	7.2
-OH	4	10	hyperreactive		109.83	7.5
	5	11	hyperreactive		109.83	
	6	12	hyperreactive		109.98	
	7	13	hyperreactive		109.78	

-OCOMe	4	14	hyperreactive		109.81	
	5	15	hyperreactive		112.39	
-NO ₂	4	16	hyperreactive		109.21	
	5	17	ND ^a		109.24	
	6	18	ND ^b		109.66	
	7	19	hyperreactive		109.16	
-NH ₂	4	20	hyperreactive		109.01	7.2
	5	21	hyperreactive		109.95	
	6	22	hyperreactive	t _{1/2} < 3 min	110.38	
	7	23	hyperreactive		109.96	
-NHCOPh	4	24	hyperreactive		110.13	
	5	25	hyperreactive	3 min < t _{1/2} < 120 min	109.66	
	6	26	ND ^b	3 min < t _{1/2} < 120 min	109.79	
	7	27	hyperreactive		109.57	

^aNot determined due to insolubility in the assay buffer.

^bNot determined due to instability in the assay buffer.

Table S2. Results of electrophilic heterocyclic library screening. Compounds with less than 50% remaining activity at 500 μM concentration are shown.

Structure	RA at 500 μM [%]
	5 ± 2
	22 ± 3
	24 ± 19
	18 ± 9
	15 ± 10









	26 ± 10
	15 ± 8
	40 ± 3
	18 ± 15
	32 ± 12
	5 ± 3
	13 ± 4

Table S3. Reactivity of benzimidazole-2-carbonitrile-containing boronic acid derivatives.



n =	X=	Y=	$R_1, R_2 =$	Label	Reactivity with <i>N</i> -acetyl cysteine (UV-Vis-based assay)	Reactivity with GSH (HPLC-based assay)
n = 1	-	-	pinanediol ester	29	ND ^a	ND ^a
n = 1	-	-	boronic acid	33	ND ^a	ND ^a
n = 2	-	-	pinanediol ester	30	not reactive	not reactive
n = 2	-	-	boronic acid	34	low absorbance	low absorbance

n = 2	-Cl	-	pinanediol ester	37	not reactive	not reactive
n = 2	-	-Cl	pinanediol ester	38	not reactive	not reactive
n = 3	-	-	pinanediol ester	31	not reactive	not reactive
n = 3	-	-	boronic acid	35	not reactive	low absorbance
n = 4	-	-	pinanediol ester	32	not reactive	not reactive
n = 4	-	-	boronic acid	36	not reactive	low absorbance

^aNot determined due to instability in the assay buffer.

Table S4. Reactivity of other boronic acid derivatives.




Structure	Label	Reactivity with <i>N</i> -acetyl cysteine (UV-Vis-based assay)	Reactivity with GSH (HPLC-based assay)
	28	low absorbance	not reactive
	39	hyperreactive	3 min < t _{1/2} < 60 min
	40	hyperreactive	low absorbance

Table S5. Determination of the IC₅₀ shift for selected bidentate compounds for the inhibition of β5i activity. Compounds were assayed without pre-incubation or with 30-min pre-incubation. PR-957 (irreversible inhibitor) was used as a control.

Pre-incubation	Compound IC ₅₀ (μM) ^a
----------------	---



(min)	30	34	38	39	PR-957
0	1.5 ± 0.3	5.1 ± 0.0	6.4 ± 0.7	3.2 ± 0.4	0.102 ± 0.006
30	0.6 ± 0.0	2.2 ± 0.6	0.6 ± 0.1	3.1 ± 0.3	0.022 ± 0.009



















^aIC₅₀ values are means from at least three independent determinations.











Table S6. Inhibitory potencies of selected benzoxazole-2-carbonitriles and bidentate ligands against hAChE, hBChE, MAO-A/B and caspase-1.



















Cpd	Residual activity [%] ± SD at 100 μM and 30 min pre-incubation ^a				
	hMAO-A	hMAO-B	hAChE	hBChE	Caspase-1
6	27 ± 0%	35 ± 1%	NA	36 ± 1%	n.d.
10	38 ± 2%	NA	27 ± 2%	NA	9 ± 3%
11	26 ± 0%	29 ± 0%	27 ± 1%	NA	0 ± 1%
13	48 ± 1%	NA	25 ± 1%	NA	5 ± 1%
14	34 ± 0%	NA	11 ± 2%	NA	49 ± 5%
15	16 ± 0%	33 ± 0%	33 ± 2%	NA	12 ± 2%
28	42 ± 0%	NA	NA	27 ± 3%	NA
30	NA	NA	NA	NA	NA
31	24 ± 0%	NA	NA	NA	NA
34	NA	NA	NA	NA	NA
35	NA	NA	NA	NA	NA
38	24 ± 1%	42 ± 0%	NA	NA	NA
39	42 ± 0%	47 ± 1%	NA	45 ± 1%	NA
40	36 ± 0%	44 ± 0%	46 ± 1%	33 ± 1%	NA











^aRAs are means from at least two independent determinations. NA, Not active (RA above 50%). n.d., not determined.




































Figure S1. Absorption spectra from the UV-Vis-based stability and reactivity assays. The first plot shows stability in aqueous solution, with significant changes indicating instability. The second plot shows reactivity with *N*-acetyl cysteine, which was determined only for compounds that are stable or intermediately stable in buffer. The third graph was used to identify hyperreactive compounds, where the reaction with *N*-acetyl cysteine is complete before the first time point can be acquired. Significant differences in the spectra of the compound in the buffer solution with or without 0.5 mM *N*-acetyl cysteine at the first time point ($t = 0$ min) indicate hyperreactivity. Stability and reactivity were not determined by this assay for compounds 5, 28 and 34 due to their low absorbance and for compound 17 due to its poor solubility.




Figure S2. Binding poses of OH- and OMe-substituted benzoxazole-2-carbonitriles form two clusters both separated by 8–9 Å from the catalytic Thr1.




Figure S3. Putative binding pose of 4-OCOMe-substituted benzoxazole-2-carbonitrile **14**. The substituent at position 4 extends toward the catalytic Thr1 residue.




Figure S4. Deconvoluted mass spectrum of reference $\beta 5i$ (PSMB8 Human) (marked with blue) and $\beta 5i$ modified by 39 (449 Da) (marked with magenta). Multiple peaks appear to be due to the presence of several mutant variants in both the reference and the modified $\beta 5i$.

References

1. Cozza, G.; Gianoncelli, A.; Bonvini, P.; Zorzi, E.; Pasquale, R.; Rosolen, A.; Pinna, L.A.; Meggio, F.; Zagotto, G.; Moro, S. Urolithin as a Converging Scaffold Linking Ellagic acid and Coumarin Analogues: Design of Potent Protein Kinase CK2 Inhibitors. *ChemMedChem* **2011**, *6*, 2273–2286, doi:10.1002/cmdc.201100338.
2. Kollár, L.; Gobec, M.; Szilágyi, B.; Proj, M.; Knez, D.; Ábrányi-Balogh, P.; Petri, L.; Imre, T.; Bajusz, D.; Ferenczy, G.G.; et al. Discovery of selective fragment-sized immunoproteasome inhibitors. *Eur. J. Med. Chem.* **2021**, *219*, doi:10.1016/j.ejmech.2021.113455.
3. Woodroffe, C.C.; Meisenheimer, P.L.; Klaubert, D.H.; Kovic, Y.; Rosenberg, J.C.; Behney, C.E.; Southworth, T.L.; Branchini, B.R. Novel heterocyclic analogues of firefly luciferin. *Biochemistry* **2012**, *51*, 9807–9813, doi:10.1021/bi301411d.
4. Möller, H. Zur Chemie 2-substituierter Benzoxazole. *Justus Liebigs Ann. Chem.* **1971**, *749*, 1–11, doi:10.1002/jlac.19717490102.
5. Kobayashi, R.; Hanaya, K.; Shoji, M.; Umezawa, K.; Sugai, T. A Chemo-Enzymatic Expeditious Route to Racemic Dihexanoyl (2R*, 3R*, 4R*)-Dehydroxymethylepoxyquinomycin (DHMEQ), the Precursor for Lipase-Catalyzed Synthesis of the Potent Nuclear Factor- κ B Inhibitor, (2S, 3S, 4S)-DHMEQ. *Chem. Pharm. Bull.* **2012**, *60*, 1220–1223, doi:10.1248/cpb.c12-00417.
6. Rubino, M.T.; Maggi, D.; Laghezza, A.; Loiodice, F.; Tortorella, P. Identification of Novel Matrix Metalloproteinase Inhibitors by Screening of Phenol Fragments Library. *Arch. Phram.*

Chem. Life Sci. **2011**, *344*, 557–563, doi:10.1002/ardp.201000350.

7. Reddy, G.L.; Sarma, R.; Liu, S.; Huang, W.; Lei, J.; Fu, J.; Hu, W. Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist. *Eur. J. Med. Chem.* **2021**, *210*, 113040, doi:10.1016/j.ejmech.2020.113040.